Topics

Fatty Liver Disease, Metabolic Disorders, and Bone Density

Metabolic Diseases Diabetes Chronic Inflammation Oxidative Stress

Metabolic dysfunction-associated steatotic liver disease (MASLD), historically studied as nonalcoholic fatty liver disease (NAFLD), is a metabolic liver disorder characterized by hepatic fat accumulation and close links with obesity, insulin resistance, dyslipidemia, metabolic syndrome, and type 2 diabetes; current work increasingly treats it as a multisystem disorder because skeletal complications can accompany liver disease. Research on the liver-bone relationship developed from evidence that obesity, diabetes, NAFLD, and osteoporosis share endocrine and inflammatory networks involving adipose tissue, liver, and bone. Pediatric work then showed that obese children with NAFLD had lower lumbar-spine bone mineral density (BMD) than matched obese controls, while later adult meta-analysis linked NAFLD with lower BMD and higher risks of osteoporosis and osteoporotic fracture. The field therefore has strong life-science relevance because fatty liver disease, metabolic disorders, bone remodeling, osteoporosis, and fragility fractures intersect in a common metabolic context[1][2][3].

Mechanistically, bone loss in MASLD reflects disturbed coupling between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. In MASLD, insulin resistance can reduce anabolic insulin-receptor signaling in osteoblasts, while proinflammatory cytokines can enhance RANK/RANKL signaling in osteoclasts, shifting remodeling toward accelerated bone loss. Broader liver-bone-adipose crosstalk involves osteopontin, osteocalcin, osteoprotegerin, fetuin-A, leptin, tumor necrosis factor-α, and adiponectin, while liver-derived signals including IGF-1 and FGF21 have also been implicated in bone homeostasis. Experimental work on hepatic osteodystrophy further showed that restoring liver-derived IGF-1 improved cortical bone acquisition, microarchitecture, and mechanical properties in a liver-specific growth-hormone-receptor knockout model, but did not restore trabecular bone volume, indicating that liver-to-bone signaling is biologically heterogeneous across skeletal compartments[1][4][5].

Disease-oriented studies support bone-health assessment as an important research and clinical application in metabolic liver disease. In adults, a systematic review and meta-analysis found NAFLD associated with decreased BMD and increased risks of osteoporosis and osteoporotic fractures; another meta-analysis likewise found higher prevalence and risk of osteoporosis or osteoporotic fracture in NAFLD. Significant liver fibrosis has also been independently associated with low BMD at the femoral neck and total hip, suggesting that fibrosis severity may identify a subgroup with greater skeletal vulnerability. Mendelian-randomization research has extended this work toward causal inference: one study identified a causal relationship between NAFLD and femoral-neck BMD or osteoporosis in replication analyses, while also showing that adjustment for body mass index eliminated several fracture-related associations. These findings position the liver-bone axis as a target for risk stratification, biomarker research, and studies of interventions that jointly address metabolic dysfunction and skeletal deterioration[3][6][7][8].

Major gaps remain because epidemiologic results are heterogeneous across age, sex, ethnicity, body mass index, skeletal site, fibrosis status, and study design, and adult MASLD data can show apparently conflicting relationships between BMD and fracture risk. The available literature also indicates that BMD alone may not capture deterioration in bone architecture, while causal pathways connecting hepatic steatosis, insulin resistance, inflammation, hepatokines, adipokines, and bone remodeling remain incompletely resolved. Future studies should therefore use prospective designs, standardized MASLD and skeletal phenotyping, fracture outcomes, bone-turnover markers, and mechanistic measurements that distinguish cortical from trabecular bone. Clarifying whether liver-directed or metabolic therapies can improve bone quality, and whether bone-active therapies influence liver disease, could translate liver-bone biology into integrated prevention and treatment strategies for MASLD, osteoporosis, and metabolic disease[4][6][8][9].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Product Guides
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-P0035A Insulin solution (human)
Insulin solution (human) is a polypeptide hormone that regulates the level of glucose. Insulin solution (human) can be used for the diabetes mellitus.
Insulin Receptor  
Metabolic or Endocrine Disease  
105
HY-P0035 Insulin (human)
Insulin (human) is a polypeptide hormone that regulates the level of glucose. Insulin (human) can be used for the diabetes mellitus.
Insulin Receptor  
Metabolic or Endocrine Disease  
105
HY-L043 Lipid Compound Library
Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies. MCE supplies a unique collection of 2,028 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

Structure Classified Libraries

84
HY-L076 Drug-Induced Liver Injury (DILI) Compound Library
Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug. DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver. MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 641 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.

Compound Characteristic Classified Libraries

84
HY-L101 Anti-Liver Cancer Compound Library
Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers. Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc. MCE offers a unique collection of 3,003 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L034M Anti-Aging Compound Library Mini
Research has shown that drugs targeting aging pathways demonstrate promising potential in models of age-related diseases such as Alzheimer's disease, cardiovascular diseases, metabolic syndrome, osteoarthritis, and various malignancies. This suggests that intervening in the biological processes of aging may enable synergistic prevention and treatment of multiple chronic diseases. Against the backdrop of the gradual elucidation of core aging mechanisms-including cellular senescence, telomere attrition, epigenetic dysregulation, and chronic inflammation anti-aging research has shifted from traditional phenotypic interventions toward targeting key pathways that regulate biological age. The MCE Anti-Aging Compound Library Mini is precisely built upon this cutting-edge concept. It focuses on aging-related targets validated through genetic or functional studies, comprising 381 compounds designed to provide systematic research tools for aging biology and intervention strategy development. The library covers core mechanisms such as mTOR, SIRT, energy metabolism, clearance of senescent cells, optimization of mitochondrial function, and telomere maintenance. For each target, 1-5 compounds with clear activity and strong representativeness have been carefully selected, spanning the entire translational spectrum from preclinical tool molecules to clinically investigational drugs.

Disease Focused Libraries

83
HY-L105 Peptide Library
Peptides are a group of biologically active substances that are involved in various cellular functions of organisms. Peptides are often used in functional analysis, vaccine research and especially in the field of drug research and development. At present, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. MedChemExpress (MCE) offers a comprehensive collection of 2,647 peptides, including bioactive peptides, amino acid derivatives, and blocking peptides. MCE Peptide Library can be used for peptide library screening, peptide drug discovery, vaccine development, target verification, structural activity research, etc.

Structure Classified Libraries

83
HY-L174 Macrophage Related Compound Library
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance. MCE designs a unique collection of 276 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

Compound Characteristic Classified Libraries

83
HY-L199 Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary. MCE designs a unique collection of 5,024 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.
83
HY-L208 Bile Acids Library
Bile acids are a class of amphiphilic molecules derived from the metabolic breakdown of cholesterol, primarily synthesized in the liver, and play a crucial role in the intestines. Based on their structural characteristics, bile acids are mainly divided into two categories: free bile acids (including Cholic acid, Deoxycholic acid, Chenodeoxycholic acid) and conjugated bile acids (including Glycocholic acid, Glycochenodeoxycholic acid, Taurocholic acid, etc.). Bile acids play a significant role in the pathophysiological research of liver and gastrointestinal diseases and are closely associated with the occurrence of metabolic diseases such as obesity, type II diabetes, non-alcoholic fatty liver disease, and atherosclerosis. Bile acids maintain metabolic balance within the body by regulating sugar metabolism, lipid metabolism, and amino acid metabolism, and they influence the activity of metabolism-related enzymes and transporters. In addition, Bile acids can also be used to construct a bile acid metabolism research platform, which helps to delve into the metabolic pathways and dynamic changes of bile acids in living organisms and aids in identifying new biomarkers for certain diseases. MCE included 62 bile acids, including Cholic acid, Deoxycholic acid, Glycocholic acid, etc., which are effective tools for the study of liver and gallbladder diseases.
83
HY-L228 Lipid Metabolite Compound Library
Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health. One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses. MCE can offer 146 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.

Metabolism Focused Libraries

83
HY-L241 Chinese Baijiu Compound Library
Chinese Baijiu is one of the oldest alcoholic beverages in the world, with a history of over 2,000 years. It can be classified into 12 aroma types based on its fragrance and flavor characteristics. The specific flavor profile of Baijiu is determined by the composition and concentration of certain compounds. These trace compounds, present in low concentrations yet rich in esters, alcohols, acids, lactones, aldehydes, ketones, acetals, alkenes, and others, significantly influence the flavor of Baijiu. Additionally, some active components in Baijiu possess antioxidant properties, and moderate consumption may help reduce the risk of cardiovascular diseases, dementia, and insulin resistance. Therefore, studying the chemical composition of Baijiu is crucial for promoting its fermentation process and enhancing its flavor and quality. MCE has compiled included 674 Chinese Baijiu components, which can be used for drug development, Baijiu fermentation, and research related to Baijiu flavor and aroma.

Compound Characteristic Classified Libraries

83
HY-L246 Tonifying Traditional Chinese Medicine Monomer Compound Library
Tonifying traditional Chinese medicines occupy a central position in the traditional medical system, with their core value lying in the regulation of the body's functional state. Modern pharmacological studies have confirmed that these medicinal materials and their monomeric components possess multiple biological activities, including bidirectional immune regulation, anti-aging and lifespan extension, neuroprotection and cognitive enhancement, as well as hematopoietic and metabolic regulation. According to the traditional Chinese medicine theory of “strengthening the body’s resistance and consolidating the foundation”, tonifying medicines are mainly classified into four major categories: Qi-tonifying, Blood-tonifying, Yin-tonifying, and Yang-tonifying. This compound library strictly follows this classification system for compound collection. Monomeric compounds derived from traditional Chinese medicines demonstrate excellent drug-like properties. They naturally possess structural diversity and clearly defined pharmacological activities, which help improve screening success rates and make them ideal tools for studying multi-target synergistic effects. This library contains 1,039 compounds, providing a material basis for investigating synergistic interactions among compounds (network pharmacology) and facilitating the development of multi-target therapeutic strategies for complex diseases such as cancer, neurodegenerative disorders, and metabolic syndrome.

Traditional Chinese Medicine Libraries

83
HY-L252 Carbohydrate Metabolite Compound Library
Carbohydrate metabolism serves as a central hub for energy supply and biosynthesis in living organisms and plays a critical role in the onset and progression of various diseases. In recent years, studies have shown that tumor cells reprogram their energy metabolism through aerobic glycolysis (the Warburg effect) to support rapid proliferation. Immune cells also rely on specific carbohydrate metabolic pathways to regulate their activation and differentiation states, while disorders such as diabetes and metabolic syndrome arise directly from dysregulation of carbohydrate metabolism. In addition, enzymes and key metabolic nodes involved in carbohydrate metabolism have become important targets for drug discovery, and therapeutic strategies targeting glycolysis, the pentose phosphate pathway, and energy metabolism are continuously advancing the treatment of cancer and metabolic diseases. Therefore, systematic analysis of carbohydrate metabolic networks and their associated metabolites is of great significance for elucidating disease mechanisms and developing novel therapeutic approaches. The MCE Carbohydrate Metabolism Metabolite Library is constructed based on classical carbohydrate metabolic pathways and contains 76 metabolites. It systematically integrates key metabolic networks, including glycolysis, the pentose phosphate pathway, the tricarboxylic acid (TCA) cycle, monosaccharide metabolism, and sugar acid interconversions. The library comprehensively covers core metabolic nodes from glucose uptake and utilization to energy production and biosynthesis, while also incorporating important upstream and downstream intermediates. It enables accurate representation of intracellular metabolic flux dynamics and is well suited for applications such as metabolic flux analysis, target validation, and mechanistic studies. Furthermore, it provides robust support for multi-omics integration and the development of precision intervention strategies.
83
HY-L263 Energy Metabolites Library
Energy metabolism is the most fundamental biochemical process in living organisms, encompassing glycolysis, the TCA cycle, oxidative phosphorylation, the pentose phosphate pathway, and fatty acid oxidation. These core pathways directly regulate cell survival, proliferation, differentiation, and apoptosis. Dysregulation of energy metabolism is closely linked to major diseases including cancer, diabetes, obesity, cardiovascular diseases, neurodegenerative disorders, and ischemia‑reperfusion injury. Targeting these metabolic pathways has become a frontier in drug discovery and mechanistic research. The MCE Energy Metabolite Compound Library features 89 structurally defined small‑molecule compounds. It covers energy substrates, pathway intermediates, coenzymes and redox carriers, nucleotide derivatives, and microenvironmental modulators. This library is applicable to research areas including tumor metabolism, insulin resistance, mitochondrial dysfunction, oxidative stress, neuroprotection, and cardiometabolic diseases, providing a high‑quality tool for mechanistic studies, biomarker discovery, and high‑throughput drug screening.

Signaling Pathway Targeting Libraries

83
HY-L265 Cholesterol Metabolism Compound Library
Cholesterol is a crucial lipid that maintains cell membrane structure, serves as a precursor for the synthesis of steroid hormones and bile acids, and plays an important role in cell signal transduction and membrane function regulation. Intracellular cholesterol levels are precisely controlled by multiple processes, including synthesis, uptake, transport, esterification, storage, and efflux. Dysregulation of cholesterol metabolism is closely associated with diseases such as atherosclerosis, fatty liver disease, metabolic syndrome, and various cancers. The Cholesterol Metabolism Compound Library contains 558 compounds and focuses on cholesterol metabolism and homeostatic regulation. It provides an efficient tool for mechanistic studies of cholesterol metabolism and for drug discovery in metabolism‑related diseases.
83
HY-B0445A NAD sodium
NAD sodium is an orally effective cofactor and homeostatic regulator. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions that oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria, which indirectly generates ATP. NAD sodium can be used for the research of non-alcoholic fatty liver disease, obesity, and glucose intolerance.
Endogenous Metabolite  
Glucose Metabolism  
53
HY-10191 Linsitinib
Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively.
IGF-1R   Insulin Receptor  
Lung Cancer   Prostate Cancer   Pancreatic Cancer   Glucose Metabolism   SARS-CoV-2 Infection  
52
HY-114118C Semaglutide sodium
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118B Semaglutide acetate
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118A Semaglutide TFA
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118 Semaglutide
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-D0711 Indocyanine green
Indocyanine green (Foxgreen) is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography (Ex/Em = 785/813 nm).
Fluorescent Dye  
Cancer  
49
HY-15656 Ceritinib
Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency.
Anaplastic lymphoma kinase (ALK)   Insulin Receptor   IGF-1R  
Metabolic or Endocrine Disease   Respiratory Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Non-Small Cell Lung Cancer  
43
HY-N0545 Taurocholic acid sodium
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
VEGFR   Endogenous Metabolite  
Inflammation or Immune System Disease   Lung Cancer   Pancreatic Cancer   Neurodegenerative Disease   Depression   Hypertension  
35
HY-B1788 Taurocholic acid
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect.
Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
35
HY-W018392 Mono-(2-ethylhexyl) phthalate
Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD).
Endogenous Metabolite  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
24
HY-W011012 Adenosine 5'-monophosphate disodium
Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.
Adenosine Receptor  
Metabolic or Endocrine Disease  
22
HY-P0299A LSKL, Inhibitor of Thrombospondin (TSP-1) TFA
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier.
TGF-β Receptor  
Cancer  
18
HY-P0299 LSKL, Inhibitor of Thrombospondin (TSP-1)
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier.
TGF-β Receptor  
Cancer  
18
HY-P1156 Insulin(cattle)
Insulin cattle is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.
Insulin Receptor  
Metabolic or Endocrine Disease  
17
HY-N0390S1 L-Glutamine-13C5
L-Glutamine-13C5 is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
13
HY-D1168 Oil Red O
Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses.
Environmental Pollutants   Fluorescent Dye  
Metabolic or Endocrine Disease   Escherichia Coli Infection  
12
HY-P0059 Teriparatide
Teriparatide (Human parathyroid hormone-(1-34)) is a PTH1 receptor agonist. Teriparatide (Human parathyroid hormone-(1-34)) can be used for osteoporosis research.
PTHR   Thyroid Hormone Receptor  
Cancer  
12
HY-N7073 Silymarin
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (Mpro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research.
SARS-CoV  
Neurological, Eye or Ear Disease   Liver Cancer   Viral Infection   Digestive System Inflammation   Obesity  
11
HY-P1944 Apelin-13
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome.
Apelin Receptor (APJ)  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
10
HY-P1944A Apelin-13 TFA
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome.
Apelin Receptor (APJ)  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
10
HY-N0681 D-Pantothenic acid hemicalcium salt
D-Pantothenic acid hemicalcium salt is an orally active vitamin that reduces patulin in apple juice. D-Pantothenic acid hemicalcium salt removes ROS. D-Pantothenic acid hemicalcium salt has antibacterial and immunomodulatory activities. D-Pantothenic acid hemicalcium salt also has the effect of improving osteoporosis and obesity.
Environmental Pollutants   Endogenous Metabolite   Apoptosis  
Metabolic or Endocrine Disease   Mycobacterium Tuberculosis Infection   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
7
HY-N0036 Costunolide
Costunolide ((+)-Costunolide) is a naturally occurring sesquiterpene lactone, with antioxidative, anti-inflammatory, antiallergic, bone remodeling, neuroprotective, hair growth promoting, anticancer, and antidiabetic properties. Costunolide can induce cell cycle arrest and apoptosis on breast cancer cells.
Apoptosis   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Digestive System Disease   Breast Cancer   Digestive System Inflammation   Glucose Metabolism  
7
HY-W018772 D-Ribose(mixture of isomers)
D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner.
Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
5
HY-N0794 Proanthocyanidins
Proanthocyanidin (Procyanidin) are a class of polyphenolic that are widely distributed in higher plants, consisted of an electrophilic flavanyl unit. Proanthocyanidin can be used as antioxidant and anti-cancers agent. Proanthocyanidin also exhibit anti-inflammatory, cardioprotective, antibacterial and antifungal properties, which can be used in the treatment of chronic venous insufficiency, capillary fragility, sunburn and retinopathy..
Bacterial   Fungal  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
5
HY-N0401A (Z)-Ligustilide
(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6. (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer.
Bacterial   Estrogen Receptor/ERR   FATP  
Infection   Metabolic or Endocrine Disease   Breast Cancer  
5
HY-100560 Abscisic acid
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H+-ATPase) and leads to the plasma membrane depolarization in a Ca2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome.

Source: Widespread

Environmental Pollutants   Proton Pump   ABA Receptor   Endogenous Metabolite  
Cancer   Glucose Metabolism  
5
HY-101410A SDMA (p-hydroxyazobenzene-p′-sulfonate)
SDMA p-hydroxyazobenzene-p′-sulfonate is the p-hydroxyazobenzene-p′-sulfonate salt form of SDMA (HY-101410). SDMA p-hydroxyazobenzene-p′-sulfonate is an endogenous inhibitor of nitric oxide synthase (NO synthase) activity. SDMA p-hydroxyazobenzene-p′-sulfonate is an activator for NF-κB, and promotes the expression of IL-6 and TNF-α. SDMA p-hydroxyazobenzene-p′-sulfonate is stable in serum and plasma, and can be used as a kidney biomarker of hepatic and renal dysfunction.
Endogenous Metabolite   NO Synthase   NF-κB  
Inflammation or Immune System Disease  
4
HY-N0772 Isomangiferin
Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective VEGFR-2 kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the HMGB1/NLRP3/NF-κB signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing.
VEGFR   NOD-like Receptor (NLR)   NF-κB   Bacterial   AMPK   Acetyl-CoA Carboxylase   Apoptosis   Reactive Oxygen Species (ROS)   HSV   Drug Derivative  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Depression   Pain   Autoimmune Disease   Digestive System Inflammation   Glucose Metabolism   Obesity   Lung Fibrosis  
4
HY-N0157C Orotic acid potassium
Orotic acid potassium (Vitamin B13 potassium) is a precursor of pyrimidine bases and is involved in the synthesis of DNA and RNA. Orotic acid potassium stimulates the growth of animals, plants and microorganisms, participates in carbohydrate metabolism, and is necessary for the growth and life activities of organisms. Orotic acid potassium is a measurement indicator in routine newborn screening for urea cycle abnormalities. Orotic acid potassium can cause hepatic steatosis and hepatomegaly in rats.
Endogenous Metabolite   DNA/RNA Synthesis  
Metabolic or Endocrine Disease  
4
HY-N0257 Epimedin A
Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases.
PI3K   Akt   NF-κB   NOD-like Receptor (NLR)   Keap1-Nrf2   Heme Oxygenase (HO)   SOD   Caspase   Interleukin Related  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
4
HY-N0390S9 L-Glutamine-15N-1
L-Glutamine-15N-1 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
4
HY-N0390S L-Glutamine-15N
L-Glutamine-15N is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
4
HY-N0157 Orotic acid
Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats.
Nucleoside Antimetabolite/Analog   Endogenous Metabolite  
Metabolic or Endocrine Disease   Lung Cancer   Leukemia/Lymphoma/Myeloma   SARS-CoV-2 Infection  
4
HY-N0457 Chicoric acid
Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects.
Reactive Oxygen Species (ROS)   Apoptosis  
Digestive System Disease   Digestive System Inflammation   Glucose Metabolism  
4
HY-P1252A Parathyroid Hormone (1-34), bovine TFA
Parathyroid Hormone (1-34), bovine TFA is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis.
Thyroid Hormone Receptor  
Metabolic or Endocrine Disease  
3
HY-P1252 Parathyroid Hormone (1-34), bovine
Parathyroid Hormone (1-34), bovine is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis.
Thyroid Hormone Receptor  
Metabolic or Endocrine Disease  
3
HY-N0914 Ajugol
Ajugol is an orally active iridoid glycoside found in the traditional Chinese medicine Leonurus japonicus. Ajugol is an autophagy activator. Ajugol activates TFEB-mediated autophagy and lysosomal biogenesis. Ajugol also has anti-inflammatory effects. Ajugol has great potential in the research of asthma, non-alcoholic fatty liver disease (NAFLD), and osteoarthritis.
Parasite   Autophagy   Interleukin Related   Reactive Oxygen Species (ROS)   mTOR  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Parasitic Infection   Pain   Digestive System Inflammation   Cardiovascular Disease   Obesity   Lung Fibrosis  
3
HY-N2181 Acetylshikonin
Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC50=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD).
Cytochrome P450   Apoptosis   Bacterial   Autophagy  
Cancer   Neurological, Eye or Ear Disease   Digestive System Disease   Bacterial Infection   Digestive System Inflammation   Glucose Metabolism  
3
HY-D0939 Direct Blue 1
Direct Blue 1 (Chicago Sky Blue 6B) is a complex dye for background autofluorescence in immunofluorescence histochemistry. Direct Blue 1 is a potent and competitive VGLUT inhibitor. Direct Blue 1 can inhibit the Aβ-binding small molecule PrP ligand. Direct Blue 1 has anti-inflammatory activity.
Amyloid-β   NF-κB  
Inflammation or Immune System Disease  
3
HY-P9958 Denosumab
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies.

Species: Human

NF-κB   Caspase   Apoptosis   RANKL/RANK  
Metabolic or Endocrine Disease   Non-Small Cell Lung Cancer   HER-2 Positive Breast Cancer   Metastatic Breast Cancer  
3
HY-42682 D(+)-Galactosamine hydrochloride
D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure.
Drug Derivative  
Inflammation or Immune System Disease  
3
HY-P10138 human GIP(3-30), amide
Human GIP(3-30), amide is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide has potential anti-obesity and anti-diabetic effects.
Insulin Receptor  
Metabolic or Endocrine Disease  
3
HY-108910 Chymotrypsin
Chymotrypsin (EC 3.4.21.1; Chymotrypsin A) is an orally effective inhibitor targeting molecules such as TLR4, NF-κB, MMP-1, TNF-α, IL-1β, and IL-6. Chymotrypsin downregulates the TLR4/NF-κB signaling pathway, inhibiting the release of inflammatory factors, reducing cell infiltration and tissue damage. It also reduces the expression of tumor cell adhesion molecules (such as CD44 and CD54) and can be specifically detected by fluorescent probes (such as NBD-3). Chymotrypsin has anti-inflammatory, hepatoprotective, joint damage-reducing, liver protection against lipotoxicity, and anti-tumor metastasis functions. It can be used in research on diseases such as rheumatoid arthritis, non-alcoholic fatty liver disease, and melanoma metastasis. Chymotrypsin can be used in studies of inflammation, edema, and expectoration.
Toll-like Receptor (TLR)   NF-κB   MMP  
Breast Cancer   Digestive System Inflammation   Gastric Disease   Metastatic Melanoma   Pharyngitis   Rheumatoid Arthritis  
3
HY-P0276 GIP, human
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion.
Insulin Receptor  
Metabolic or Endocrine Disease  
3
HY-P10769 MOTS-c (mouse)
MOTS-c (mouse) is a mitochondrial-derived polypeptide that can be used to regulates pancreatic cell function. MOTS-c (mouse) reduces insulin secretion and expression in INS-1E cells, and enhances glucagon secretion and expression in αTC-1 cells. MOTS-c (mouse) decreases the apoptosis in INS-1E and αTC-1. MOTS-c (mouse) counteracts diet-induced obesity and insulin resistance through AMPK activation.
AMPK   Apoptosis  
Pancreatic Cancer   Pain   Digestive System Inflammation   Obesity  
2
HY-N0818 Chikusetsusaponin Iva
Chikusetsusaponin IVa is an orally active protein kinase activator. Chikusetsusaponin IVa binds to YAP with a KD value of 0.388 mM. Chikusetsusaponin IVa reduces inflammatory mediators (IL-6, IL-10, COX-2) expression, NO production, promotes ROS generation, induces Apoptosis, inhibits MAPK, TAZ, and regulates Nrf2, JAK/STAT. Chikusetsusaponin Iva has anti-H9N2 AIV and anti-endometrial cancer activities. Chikusetsusaponin Iva shows anti-inflammatory, hepatoprotective and osteoprotective effects.
Keap1-Nrf2  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Colorectal Cancer   Prostate Cancer   Ovarian Cancer   Depression   Pain  
2
HY-N0433 Astragaloside II
Astragaloside II is an orally active Cycloartane-type triterpene glycoside. Astragaloside II can be extracted from Astragalus membranaceus. Astragaloside II inhibits Autophagy, decreases pro-inflammatory cytokines (IL-6, IL-1β), HIF-α, p-p65, p-IκB and increases SOD. Astragaloside II regulates immunity and reduces inflammatory responses. Astragaloside II can be used in the research of diseases such as liver cancer, osteoporosis, immunosuppressive diseases, and ulcerative colitis.
Autophagy   Interleukin Related   HIF/HIF Prolyl-Hydroxylase   SOD   NF-κB  
Liver Cancer   Pain   Osteoporosis   Ulcerative Colitis  
2
HY-N1419 Vaccarin
Vaccarin is an orally active flavonoid glycoside with multiple biological functions. Vaccarin promotes neovascularization by activating AKT and ERK. Vaccarin activates the AMPK signaling pathway to improve insulin resistance and steatosis. Vaccarin is a MAPK, NF-κB, and NFAT inhibitor, effectively blocking RANKL-induced osteoclastogenesis.
AMPK   Akt   ERK   p38 MAPK   NF-κB   Nuclear Factor of activated T Cells (NFAT)   JNK  
Lung Cancer   Breast Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
2
HY-D0848 N,N'-Methylenebisacrylamide
N,N'-Methylenebisacrylamide (Bisacrylamide) is an orally active acrylamide dimer and crosslinker. N,N'-Methylenebisacrylamide increases CYP2E1, P53, cleaved caspase-3. N,N'-Methylenebisacrylamide promotes hepatic cancer. N,N'-Methylenebisacrylamide changes sperm abnormality rate and sperm count. N,N'-Methylenebisacrylamide decreases the number of various cells in the blood as well as induces liver and testicular damage. N,N'-Methylenebisacrylamide is used to prepare polyacrylamide gel.
Biochemical Assay Reagents   MDM-2/p53   Caspase  
Cancer   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
2
HY-114360 Taurohyodeoxycholic acid
Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula.
Endogenous Metabolite   COX   Interleukin Related   Glutathione Peroxidase   TNF Receptor  
Metabolic or Endocrine Disease   Digestive System Disease   Prostate Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
2
HY-N2118 Bilobetin
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.
PPAR   PKA   Akt   p38 MAPK   ERK  
Metabolic or Endocrine Disease   Lung Cancer   Pancreatic Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation  
2
HY-P7507 ANGPTL4/Angiopoietin-related 4 Protein, Human (HEK293, His)
Angiopoietin-like protein 4, Human modulates the disposition of circulating triglycerides (TG) by inhibiting lipoprotein lipase (LPL). Angiopoietin-Related Protein 4 is a conventional, non-competitive inhibitor that binds to LPL to prevent the hydrolysis of substrate as part of reversible mechanism.

Species: Human; Source: HEK293

Cytokines and Growth Factors Angiopoietins Angiopoietin Like 4

2
HY-W127601 Lard oil
Lard oil is an orally active biochemical reagent. Lard oil upregulates PERK, eIF2a, CHOP, OPN, TLR2, TLR4, TNF-α, and downregulates GRP78 and IRE1a. Lard oil induces responses such as body fat accumulation, elevated serum insulin levels, increased HOMA-IR, hepatic ectopic lipid deposition, hepatic endoplasmic reticulum stress, and hepatic inflammation. Lard oil can be used in studies related to diet-induced obesity, insulin resistance, and non-alcoholic fatty liver disease.
Biochemical Assay Reagents   PERK   Eukaryotic Initiation Factor (eIF)   Toll-like Receptor (TLR)   TNF Receptor   IRE1  
Insulin Resistance   Obesity  
1
HY-W018392S Mono-(2-ethylhexyl) phthalate-d4
Mono-(2-ethylhexyl) phthalate-d4 is a deuterium labeled Mono-(2-ethylhexyl) phthalate (HY-W018392). Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD).
Isotope-Labeled Compounds   Endogenous Metabolite  
Metabolic or Endocrine Disease  
1
HY-N0608 Myrislignan
Myrislignan is a PI3K/AKT/NF-κB inhibitor that can cross the blood-brain barrier. Myrislignan exerts anticancer activity by inducing apoptosis and ferroptosis. Myrislignan inhibits the replication and invasion of Toxoplasma gondii; it induces reactive oxygen species (ROS) imbalance, autophagy, and the death of Toxoplasma gondii tachyzoites. Myrislignan inhibits mitochondrial function and ERK1/2 phosphorylation to improve ovariectomy-induced osteoporosis. Myrislignan can be used in studies related to gastric cancer, glioblastoma, osteoporosis, and toxoplasmosis.
NF-κB   PI3K   Akt   Apoptosis   Ferroptosis   Reactive Oxygen Species (ROS)   Autophagy   ERK  
Gastric Cancer   Glioblastoma   Toxoplasma Infection   Osteoporosis  
1
HY-N0390S5 L-Glutamine-1-13C
L-Glutamine-1-13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
1
HY-B1134 Imazalil
Imazalil (Enilconazole) is a fungicide. Imazalil has oral activity and strongly activates mPXR but not mCAR in mouse liver. Imazalil is commonly used to protect various agricultural crops against fungal attack. Imazalil induces developmental abnormalities, gut microbiota dysbiosis, and hepatic metabolism disorder.
Environmental Pollutants   Pregnane X Receptor (PXR)   Fungal  
Fungal Infection  
1
HY-113133 Kojibiose
Kojibiose, an orally active prebiotic disaccharide, can specifically inhibit the activity of α-glucosidase I. kojibiose is a proliferation factor for Bifidobacterium, lactic acid bacteria, and eubacteria. kojibiose is a low-calorie sweetener capable of increasing the absorption of iron. Kojibiose exhibits antitoxic activity. Kojibiose reduces hepatic expression of inflammatory markers in vivo.

Source: Mortierella alliacea Linnem

Glycosidase  
Inflammation or Immune System Disease   Bacterial Infection  
1
HY-N6869 Dehydroabietic acid
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice.
Antibiotic   PPAR   Bacterial   Fungal  
Cancer   Metabolic or Endocrine Disease   Digestive System Disease   Bacterial Infection   Fungal Infection   Digestive System Inflammation  
1
HY-N0723 Neomangiferin
Neomangiferin is an orally active natural flavonoid. Neomangiferin partially ameliorates non-alcoholic fatty liver disease (NAFLD) by regulating the expression of genes related to free fatty acid uptake and lipid oxidation. Neomangiferin exerts anti-colitis effects by inhibiting Th17/Treg cell differentiation. Neomangiferin exerts anti-aging and lifespan-extending effects by targeting upregulation of bas-1, which in turn activates the autophagy, IIS and MAPK pathways. Neomangiferin has the potential to prevent aseptic loosening of prostheses after total joint arthroplasty due to its significant anti-inflammatory and osteoclastogenesis-inhibiting effects.
Autophagy   p38 MAPK   TNF Receptor   Interleukin Related   PPAR  
Digestive System Disease   Colitis   Fatty Liver Disease   Osteoporosis  
1
HY-N5139 Lecithins, egg
Lecithins, egg (Lecithins, egg yolk; Belovo PL 85) is an orally active natural phospholipid mixture extracted from egg yolks. Lecithins, egg inhibits the activities of acetylcholinesterase (AChE) and angiotensin-converting enzyme (ACE). Lecithins, egg exhibits antibacterial, antioxidant and anti-inflammatory activities, and helps delay cellular senescence. Lecithins, egg enhances nerve conduction, improves memory and cognitive function, and exerts positive effects on delaying neurodegenerative diseases. Lecithins, egg promotes lipid absorption and alleviates diarrhea. Lecithins, egg acts as a high-efficiency drug carrier for the preparation of targeted drug delivery systems such as liposomes.
Cholinesterase (ChE)   Angiotensin-converting Enzyme (ACE)   Bacterial  
Digestive System Disease   Bacterial Infection   Neurodegenerative Disease   Oxidative Stress and Inflammation   Lipid Metabolism  
1
HY-106373A Adrenocorticotropic hormone TFA
Adrenocorticotropic hormone (ACTH; Adrenocorticotrophic hormone) TFA is a polypeptide tropic hormone produced by the anterior pituitary gland. Adrenocorticotropic hormone TFA stimulates cortisol secretion from the adrenal cortex via the hypothalamic-pituitary-adrenal (HPA) axis. Adrenocorticotropic hormone TFA regulates cortisol and androgen production. Adrenocorticotropic hormone TFA can promote the development of spermatogenesis. Adrenocorticotropic hormone TFA can relieve acute inflammation in gout models by inhibiting the polarization of macrophages to M1 type, inhibiting ROS and proinflammatory factor production and protecting mitochondrial function. Adrenocorticotropic hormone TFA can be used for the researches of inflammation, endocrinology, metabolic disease, such as gout and nephrotic syndrome.
Androgen Receptor   Reactive Oxygen Species (ROS)   Mitochondrial Metabolism   Interleukin Related   TNF Receptor  
Inflammation or Immune System Disease   Gout  
1
HY-W018499 (S)-2-Hydroxybutanoic acid
(S)-2-Hydroxybutanoic acid is the S-enantiomer of 2-Hydroxybutanoic acid. 2-Hydroxybutanoic acid, a coproduct of protein metabolism, is an insulin resistance (IR) biomarker.
Endogenous Metabolite  
1
HY-W105750 6-Hydroxyhexanoic acid
6-Hydroxyhexanoic acid (6-HHA) is a bacterial effector molecule with metabolic and immunomodulatory activities. 6-Hydroxyhexanoic acid activates the JAK1-STAT1 signaling pathway, promotes phenotypic conversion of M2 macrophages to M1 macrophages, and exerts anti-tumor effects by regulating macrophage polarization. 6-Hydroxyhexanoic acid inhibits lipolysis in adipocytes mediated by Gαi family GPCR, and reduces high-fat diet-induced weight gain and obesity. 6-Hydroxyhexanoic acid can be used in studies related to pancreatic ductal adenocarcinoma, obesity, and insulin resistance.
JAK   STAT   Adenylate Cyclase  
Pancreatic Ductal Adenocarcinoma   Insulin Resistance   Obesity  
1
HY-N0732 Jolkinolide B
Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
IAP   Akt   Caspase   NF-κB   TGF-beta/Smad   JAK   Bacterial   Apoptosis  
Cancer   Mycobacterium Tuberculosis Infection   Asthma   Fatty Liver Disease  
1
HY-W592871 10-Hydroxy-2-decenoic acid
10-Hydroxy-2-decenoic acid (10-HDA) is an orally active unsaturated medium-chain fatty acid with various physiological activities. 10-Hydroxy-2-decenoic acid induces ROS-mediated apoptosis in A549 cells. 10-Hydroxy-2-decenoic acid inhibits VEGF-induced angiogenesis in human venous endothelial cells. 10-Hydroxy-2-decenoic acid alleviates non-alcoholic fatty liver disease (NAFLD) by activating the AMPK-α signaling pathway. 10-Hydroxy-2-decenoic acid protects against bone loss by inhibiting NF-κB signaling downstream of FFAR4. 10-Hydroxy-2-decenoic acid is an antibiotic against many bacteria and fungi, such as Neurospora sitophila, molds and Staphylococcus aureus. 10-Hydroxy-2-decenoic acid has longevity-promoting effects in C. elegans. 10-Hydroxy-2-decenoic acid prevents osteoarthritis by targeting aspartyl β hydroxylase and inhibiting chondrocyte senescence.

Source: Royal Jelly

mTOR   Apoptosis   ERK   MDM-2/p53   GSK-3   AMPK   Interleukin Related   TNF Receptor   Caspase   NF-κB   Bacterial   Fungal  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Bacterial Infection   Fungal Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Alzheimer's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
1
HY-N0390S2 L-Glutamine-d5
L-Glutamine-d5 is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
1
HY-106373 Adrenocorticotropic hormone
Adrenocorticotropic hormone (ACTH; Adrenocorticotrophic hormone) is a polypeptide tropic hormone produced by the anterior pituitary gland. Adrenocorticotropic hormone stimulates cortisol secretion from the adrenal cortex via the hypothalamic-pituitary-adrenal (HPA) axis. Adrenocorticotropic hormone regulates cortisol and androgen production. Adrenocorticotropic hormone can promote the development of spermatogenesis. Adrenocorticotropic hormone can relieve acute inflammation in gout models by inhibiting the polarization of macrophages to M1 type, inhibiting ROS and proinflammatory factor production and protecting mitochondrial function. Adrenocorticotropic hormone can be used for the researches of inflammation, endocrinology, metabolic disease, such as gout and nephrotic syndrome.
Androgen Receptor   Reactive Oxygen Species (ROS)   Mitochondrial Metabolism   Interleukin Related   TNF Receptor  
Inflammation or Immune System Disease   Gout  
1
HY-15927 4-Nitrophenyl β-D-glucopyranoside
4-Nitrophenyl β-D-glucopyranoside is a chromogenic substrate for β-glucosidase. 4-Nitrophenyl β-D-glucopyranoside is converted to a colored product, p-nitrophenol that is easily detected spectrophotometrically at 405 nm when used in a β-glycosidase assay. 4-Nitrophenyl β-D-glucopyranoside is hydrolysed through intramolecular nucleophilic catalysis by the phosphate group in the 2-position. 4-Nitrophenyl β-D-glucopyranoside is promising for research of postmenopausal osteoporosis.
Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
1
HY-W250122 Glutamic acid sodium salt
Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders.
Biochemical Assay Reagents   Reactive Oxygen Species (ROS)   Mitochondrial Metabolism   Apoptosis   HSP   Bcl-2 Family  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-W012980 Isovaleric acid
Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders.
Endogenous Metabolite   AMPK   PKA  
Pancreatic Cancer   Osteoporosis  
1
HY-N0390S8 L-Glutamine-15N2
L-Glutamine-15N2 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
1
HY-133707 β-Muricholic acid
β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD).
Endogenous Metabolite  
Digestive System Disease   Digestive System Inflammation  
1
HY-P9982 Romosozumab
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis.

Species: Human

Others  
Cancer   Metabolic or Endocrine Disease  
1
HY-W012734 L-Pipecolic acid
L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
1
HY-113381 2-Hydroxybutyric acid
2-Hydroxybutyric acid (α-Hydroxybutyric acid ) is converted from 2-Aminobutyric acid, with 2-oxobutyric acid as an intermediate metabolite. 2-Hydroxybutyric acid is a potential biomarker for type 2 diabetes and preeclampsia. 2-Hydroxybutyric acid prevents the acetaminophen (AP)-induced liver injury.
Endogenous Metabolite  
Glucose Metabolism  
1
HY-W013215 Adrenic acid
Adrenic Acid (cis-7,10,13,16-Docosatetraenoic acid) is a naturally polyunsaturated fatty acid in the adrenal gland, brain, kidney, and vasculature. Adrenic Acid can regulate the vascular tone in arteries of the adrenal cortex. Adrenic Acid also is an inflammation enhancer in non-alcoholic fatty liver disease.
Endogenous Metabolite  
Digestive System Disease   Digestive System Inflammation  
1
HY-P70146 Ketohexokinase/KHK Protein, Human (HEK293, His)
Ketohexokinase (KHK) proteins play a key role in carbohydrate metabolism by catalyzing the phosphorylation of ketoglycosides into fructose-1-phosphate. This enzyme activity is a key step in the utilization and processing of fructose within cells. Ketohexokinase/KHK Protein, Human (HEK293, His) is the recombinant human-derived Ketohexokinase/KHK protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

Enzymes & Regulators Transferases (EC 2)

1
HY-P11274 Zenagamtide
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
Amylin Receptor   GCGR   Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-W1126955 Enlicitide decanoate
Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease.
PCSK9  
Atherosclerosis and Inflammation   Hypercholesterolemia  
/
HY-18719S Endoxifen-d5 (Z-isomer)
Endoxifen-d5 (Z-isomer) is the deuterated-labeled Endoxifen (Z-isomer methanesulfonate) (HY-18719H). Endoxifen-d5 Z-isomer is an orally active selective PKCβ1 inhibitor with an IC50 of 360 nM against human PKCβ1. It also acts as an estrogen receptor modulator and antiestrogen. Endoxifen-d5 Z-isomer binds to and blocks ERα, ERβ and PKCβ1, inhibits estrogen and PI3K/AKT/mTORC1 signaling pathways, suppresses the expression of genes associated with cell cycle, cell proliferation and extracellular matrix remodeling, and induces apoptosis, reactive oxygen species (ROS) production and hypoxic features. Endoxifen-d5 Z-isomer inhibits tumor growth in breast tumor and glioblastoma models, reduces bone turnover and blood lipid levels, and does not require metabolism via CYP2D6. It can be used in research related to ER+ breast cancer, invasive breast cancer, glioblastoma multiforme, type I bipolar disorder, desmoid tumor, gynecological malignancies, melanoma and hormone receptor-positive solid tumors
PKC   Estrogen Receptor/ERR   PI3K   Akt   mTOR   Apoptosis   Reactive Oxygen Species (ROS)  
Breast Cancer   Melanoma   Glioblastoma  
/
HY-W012722BS 4-Methyl-2-oxopentanoic acid-d7 sodium
4-Methyl-2-oxopentanoic acid-d7 (α-Ketoisocaproic acid-d7) sodium is the deuterium labeled 4-Methyl-2-oxopentanoic acid (HY-W012722).4-Methyl-2-oxopentanoic acid is a metabolite of L-leucine and is involved in energy metabolism. 4-Methyl-2-oxopentanoic acid increases endoplasmic reticulum stress, promotes lipid accumulation in preadipocytes and insulin resistance by impairing mTOR and autophagy signaling pathways.
Endogenous Metabolite   Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-B0515AS1 Ibandronic acid-d3
Ibandronic acid-d3 is the deuterium labeled Ibandronic acid. Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
Apoptosis   Isotope-Labeled Compounds  
Cancer  
/
HY-P3637 AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG
AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG promotes bone-ossification. AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG can be used in the research of diseases or disorders related to osteogenic defects or bone mineral density (BMD) decreasing, such as osteoporosis.
Others  
Inflammation or Immune System Disease  
/
HY-N15602 Isosojagol
Isosojagol (Compound 5) is a α-Glucosidase inhibitor with an IC50 of 32.2  μM. Isosojagol can be isolated from the Roots of Dolichos trilobus. Isosojagol has anti-inflammatory activity and inhibits LPS (HY-D1056A1)-induced NO production in RAW264.7 cells. Isosojagol can be used for fracture, soft tissue injuries and rheumatoid arthritis research.
Glycosidase   NO Synthase  
Inflammation or Immune System Disease  
/
HY-P3580 Acetyl Gastric Inhibitory Peptide (human)
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.
Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-W018772S D-Ribose-18O
D-Ribose-18O is the 18O labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-P3866 [Asu1,6]-Oxytocin
[Asu1,6]-Oxytocin is an analog of oxytocin. [Asu1,6]-Oxytocin reverses insulin resistance and glucose intolerance prior to reduction of obesity. [Asu1,6]-Oxytocin has the potential for the research of obesity and diabetes.
Oxytocin Receptor  
Metabolic or Endocrine Disease  
/
HY-P4815 Prokineticin 2 Isoform 2 (human)
Prokineticin 2 Isoform 2 (human) is a hypothalamic neuropeptide. Prokineticin 2 Isoform 2 (human) decreases food intake and involves in thermoregulation and energy metabolism in rodents. Prokineticin 2 has the potential for the research of hyperglycemia, metabolic syndrome (MetS) and obesity.
Endogenous Metabolite  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P10305 Visepegenatide
PB-119 is a PEGylated Exenatide. PB-119 decreases glycemic levels by improving beta-cell function and insulin resistance. PB-119 can be used for research of type 2 diabetes.
Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-N3686S1 D-Arabitol-13C-1
D-Arabitol-13C-1 is the 13C labeled D-Arabitol. D-Arabitol is an orally active D-enantiomer of arabitol. D-Arabitol modulates the composition of gut microbiota, increases short-chain fatty acids, and promotes AMPK-PGC-1α-related browning of white adipose tissue. D-Arabitol improves weight gain, fat accumulation, insulin resistance, lipid deposition and inflammatory responses. D-Arabitol serves as the sole carbon/energy source for Bacillus methanolicus MGA3, a strain that can co-utilize it with mannitol. D-Arabitol is applicable to obesity-related research.
Isotope-Labeled Compounds   AMPK   PGC-1α  
Metabolic or Endocrine Disease  
/
HY-P991362 GB-223
GB-223 is a human monoclonal antibody (mAb) targeting TNFSF11/RANKL/CD254. GB-223 can be used in Giant cell tumour of bone and Postmenopausal osteoporosis research.

Species: Human

TNF Receptor  
Cancer  
/
HY-N3686S D-Arabitol-13C
D-Arabitol-13C is the 13C labeled D-Arabitol. D-Arabitol is an orally active D-enantiomer of arabitol. D-Arabitol modulates the composition of gut microbiota, increases short-chain fatty acids, and promotes AMPK-PGC-1α-related browning of white adipose tissue. D-Arabitol improves weight gain, fat accumulation, insulin resistance, lipid deposition and inflammatory responses. D-Arabitol serves as the sole carbon/energy source for Bacillus methanolicus MGA3, a strain that can co-utilize it with mannitol. D-Arabitol is applicable to obesity-related research.
Isotope-Labeled Compounds   AMPK   PGC-1α  
Metabolic or Endocrine Disease  
/
HY-N0608S Myrislignan-13C,d2
Myrislignan-13C,d2 is the 13C, d2 deuterated-labeled Myrislignan (HY-N0608). Myrislignan is a PI3K/AKT/NF-κB inhibitor that can cross the blood-brain barrier. Myrislignan exerts anticancer activity by inducing apoptosis and ferroptosis. Myrislignan inhibits the replication and invasion of Toxoplasma gondii; it induces reactive oxygen species (ROS) imbalance, autophagy, and the death of Toxoplasma gondii tachyzoites. Myrislignan inhibits mitochondrial function and ERK1/2 phosphorylation to improve ovariectomy-induced osteoporosis. Myrislignan can be used in studies related to gastric cancer, glioblastoma, osteoporosis, and toxoplasmosis.
Isotope-Labeled Compounds   NF-κB   PI3K   Akt   Apoptosis   Ferroptosis   Reactive Oxygen Species (ROS)   Autophagy   ERK  
Gastric Cancer   Glioblastoma   Toxoplasma Infection   Osteoporosis  
/
HY-163263S1 HSD17B13-IN-80-d2
HSD17B13-IN-80-d2 (Compound 200) is the the deuterium labeled HSD17B13-IN-80 (HY-163263). HSD17B13-IN-80 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
17β-HSD  
Metabolic or Endocrine Disease  
/
HY-N3686S2 D-Arabitol-13C-2
D-Arabitol-13C-2 is the 13C labeled D-Arabitol. D-Arabitol is an orally active D-enantiomer of arabitol. D-Arabitol modulates the composition of gut microbiota, increases short-chain fatty acids, and promotes AMPK-PGC-1α-related browning of white adipose tissue. D-Arabitol improves weight gain, fat accumulation, insulin resistance, lipid deposition and inflammatory responses. D-Arabitol serves as the sole carbon/energy source for Bacillus methanolicus MGA3, a strain that can co-utilize it with mannitol. D-Arabitol is applicable to obesity-related research.
Isotope-Labeled Compounds   AMPK   PGC-1α  
Metabolic or Endocrine Disease  
/
HY-W012856 3-Ethyltoluene
3-Ethyltoluene (3-Methylethylbenzene) is an isomer of Ethyltoluenes. 3-Ethyltoluene inhibits cell survival and proliferation and increases ROS production. 3-Ethyltoluene upregulates cellular inflammatory gene expression. 3-Ethyltoluene induces cell fibrosis with increased level of AST, FGF-23, Cyt-7 p21, TGFβ, TIMP2, and MMP2. 3-Ethyltoluene can be used for liver diseases such as NAFLD research.
Reactive Oxygen Species (ROS)   FGFR   TGF-β Receptor   MMP  
Fatty Liver Disease  
/
HY-145581S Mitiperstat-d3
Mitiperstat-d3 (AZD4831-d3) is the deuterated -labeled Mitiperstat (HY-145581).Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease.
Isotope-Labeled Compounds   Glutathione Peroxidase   Cytochrome P450  
Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease   Chronic Obstructive Pulmonary Disease  
/
HY-N16480 Lindetannin
Lindetannin (Lindetannin trimer) is an A-type trimer of proanthocyanidin (HY-N0794) found in the bark of Cinnamomum trees. Proanthocyanidin are a class of polyphenolic that are widely distributed in higher plants, consisted of an electrophilic flavanyl unit. Proanthocyanidin can be used as antioxidant and anti-cancer agent. Proanthocyanidin also exhibit anti-inflammatory, cardioprotective, antibacterial and antifungal properties, which can be used in the treatment of chronic venous insufficiency, capillary fragility, sunburn and retinopathy.
Drug Derivative   Bacterial   Fungal  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-163263S HSD17B13-IN-80-d3
HSD17B13-IN-80-d3 (179) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
17β-HSD  
Metabolic or Endocrine Disease  
/
HY-N0390G L-Glutamine (GMP)
L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
mTOR   NF-κB   STAT   HIF/HIF Prolyl-Hydroxylase  
Inflammation or Immune System Disease   Ischemic Stroke   Osteoporosis   Osteoarthritis  
/
HY-B2156S1 Menaquinone-4-13C6
Menaquinone-4-13C6 is the 13C-labeled Menaquinone-4. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer  
/
HY-P992072 Anti-Human/Mouse CD95 Antibody (HFE7A)
Anti-Human/Mouse CD95 Antibody (HFE7A) is an antibody targeting human/mouse Fas (CD95), with a Kd of 1.6 nM in mice. Anti-Human/Mouse CD95 Antibody (HFE7A) modulates the Fas-mediated apoptotic signaling pathway without blocking the binding of Jo2 to Fas. Anti-Human/Mouse CD95 Antibody (HFE7A) inhibits Jo2-induced caspase activation, mitochondrial depolarization, hepatocyte death and apoptosis. Anti-Human/Mouse CD95 Antibody (HFE7A) protects BALB/c mice against Jo2-induced acute liver injury and reduces Jo2-associated elevation of serum transaminase levels. Anti-Human/Mouse CD95 Antibody (HFE7A) can be used in studies related to liver injury. For isotype control, refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).

Species: Human/Mouse

Apoptosis   Caspase  
Liver Injury  
/
HY-10585AG Valproic acid sodium (GMP)
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
Organoid   HDAC   Autophagy   Mitophagy   HIV   Notch   Apoptosis   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-W018392R Mono-(2-ethylhexyl) phthalate (Standard)
Mono-(2-ethylhexyl) phthalate (Standard) is the analytical standard of Mono-(2-ethylhexyl) phthalate. This product is intended for research and analytical applications. Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD).
Reference Standards   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-153476 GIP/GLP-1 dual receptor agonist-1
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
GCGR   GLP Receptor  
Digestive System Disease   Digestive System Inflammation  
/
HY-P11818 GIPR/GLP-1R/GCGR agonist-1
GIPR/GLP-1R/GCGR agonist-1 (compound 686) is a triple receptor agonist with activity at GLP-1R, GIPR, and GCGR. GIPR/GLP-1R/GCGR agonist-1 functionally modulates target receptors to drive cAMP generation. GIPR/GLP-1R/GCGR agonist-1 can be used for the research of type 2 diabetes mellitus, obesity, nonalcoholic fatty liver disease.
GLP Receptor   GCGR  
Digestive System Disease   Digestive System Inflammation   Type 2 Diabetes   Obesity  
/
HY-P5762A Phoenixin-14 TFA
Phoenixin-14 (PNX-14) TFA is an endogenous neuropeptide with multiple biological activities, and serves as the endogenous ligand of GPR173. Phoenixin-14 TFA reduces ROS production by inhibiting the HMGB1/TLR4/MyD88/NF-κB signaling axis, thereby exerting antioxidant and mitochondrial protective effects. Phoenixin-14 TFA inhibits FOXO3 phosphorylation by upregulating SIRT3 expression, suppresses apoptosis, and improves myocardial systolic/diastolic function. Phoenixin-14 TFA resists ferroptosis by activating the ATF4/SLC7A11/GPX4 axis; it activates ERK1/2 phosphorylation via GPR173. Phoenixin-14 TFA can be used in researches on neuroprotection, diabetes, cardiomyopathy, reproductive protection and so on.
Reactive Oxygen Species (ROS)   Orphan GPCR   ERK   FOXO   MyD88   NF-κB   Ferroptosis   Sirtuin   PKA   Apoptosis   Glutathione Peroxidase   Toll-like Receptor (TLR)   Akt  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-18252S1 Avanafil-13C5,15N,d2
Avanafil-13C5,15N,d2 is 15N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
Isotope-Labeled Compounds   NO Synthase   Endogenous Metabolite   Phosphodiesterase (PDE)  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-Y1009S Methoxyacetic acid-d3
Methoxyacetic acid-d3 is the deuterium labeled Methoxyacetic acid (HY-Y1009). Methoxyacetic acid is a metabolite of ethylene glycol monomethyl ether. When the concentration of methoxyacetic acid reaches a certain level, it can inhibit the respiratory function of hepatic mitochondria and testicular mitochondria. Methoxyacetic acid is somewhat toxic.
Isotope-Labeled Compounds   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-DY1027 Indocyanine green (solution)
Indocyanine green (Foxgreen) (solution) is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography (Ex/Em = 785/813 nm) .
Solvent and concentration: DMSO: 10 mM
Fluorescent Dye  
/
HY-P11612 ATS-9R
ATS-9R is a peptide consisting of an adipocyte-targeting sequence and D-form 9-arginine. ATS-9R selectively transfects mature adipocytes by binding to prohibitin. ATS-9R allows an adipocyte-targeted gene delivery in vitro and in vivo. ATS-9R can be used for the development of an adipocyte-targeted gene carrier. ATS-9R can be used for the study of obesity as well as obesity-induced metabolic syndromes.
Biochemical Assay Reagents  
Obesity  
/
HY-P5390 GIP, rat
GIP, rat is a bioactive peptide derived from rats. GIP, rat inhibits GIP-mediated postprandial insulin release as well as GIP-promoted glucose uptake in the upper small intestine. GIP, rat can be used in research related to insulin resistance, glucose intolerance, and type 2 diabetes.
Insulin Receptor   Glycosidase  
Type 2 Diabetes   Insulin Resistance  
/
HY-163259S HSD17B13-IN-62-d3
HSD17B13-IN-62-d3 (176) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
17β-HSD  
Metabolic or Endocrine Disease  
/
HY-P11830 UDA-6
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity.
Amylin Receptor  
Obesity  
/
HY-W018772S7 D-Ribose-d-1
D-Ribose-d-1 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-109089S Epeleuton-d5
Epeleuton-d5 (15(S)-HEPE-d5 ethyl ester) is deuterium labeled Epeleuton. Epeleuton is a second-generation synthetic N-3 fatty acid derivative with activity in patients with non-alcoholic fatty liver disease, although it did not reach the primary endpoints of alanine aminotransferase and liver stiffness, but it can significantly reduce triglycerides, glycated hemoglobin, plasma glucose and inflammatory markers.
Isotope-Labeled Compounds  
/
HY-P11075 [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10)
[Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) (ID 305) is a selective NK2R agonist with an EC50 of 3.7  nM for hNK2R. [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) significantly inhibits weight loss in diet-induced obese (DIO) mice model and improves Loperamide (HY-156131)-induced dysfunctional voiding in wild-type mice. [Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) can be used for neurokinin receptor mediated disorders, such as obesity, insulin resistance and type 2 diabetes research.
Neurokinin Receptor  
Metabolic or Endocrine Disease  
/
HY-W018772S4 D-Ribose-13C-3
D-Ribose-13C-3 is the 13C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-N12836 Peniditerpenoid A
Peniditerpenoid A is a di-seco-indole diterpenoid. Peniditerpenoid A decreases the expression of p-IkBαby RANKL induced. Peniditerpenoid A inhibits RANKL induced osteoclast differentiation. Peniditerpenoid A has the potential for the research of osteoporosis.

Source: Mangrove Sediment-Derived Penicillium sp.

Others  
Metabolic or Endocrine Disease  
/
HY-P991659 SCH708980
SCH708980 is a humanized monoclonal antibody inhibitor targeting IL-10. SCH708980 has anti-immunosuppressive activity. SCH708980 can be used for visceral leishmaniasis, sepsis-associated kidney injury (SAKI) and osteoporosis research.

Species: Human

Interleukin Related  
Infection   Inflammation or Immune System Disease  
/
HY-P3829 Beacon (47-73)
Beacon (47-73) is a C-terminal peptide fragment 47-73 of Beacon, and Beacon is a protein of 73 amino acid. Beacon (47-73) can be used for metabolic syndrome research.
Others  
Metabolic or Endocrine Disease  
/
HY-P5377 Abz-HPGGPQ-EDDnp
Abz-HPGGPQ-EDDnp (Cathepsin K substrate) is a biological active peptide. (Cathepsins are a class of globular lysosomal proteases, playing a vital role in mammalian cellular turnover. They degrade polypeptides and are distinguished by their substrate specificities. Cathepsin K is the lysosomal cysteine protease involved in bone remodeling and resorption. It has potential as a drug target in autoimmune diseases and osteoporosis.This FRET peptide can be used to monitor selectively cathepsin K activity in physiological fluids and cell lysates. Abz-HPGGPQ-EDDnp [where Abz represents o-aminobenzoic acid and EDDnp represents N -(2, 4-dinitrophenyl)-ethylenediamine], a substrate initially developed for trypanosomal enzymes, is efficiently cleaved at the Gly-Gly bond by cathepsin K. This peptide is resistant to hydrolysis by cathepsins B, F, H, L, S and V, Ex/Em=340 nm/420 nm.)
Ser/Thr Protease  
/
HY-10003S Alfacalcidol-d7
Alfacalcidol-d7 is the deuterium labeled Alfacalcidol. Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis.
Isotope-Labeled Compounds   VD/VDR  
Metabolic or Endocrine Disease  
/
HY-W011012R Adenosine 5'-monophosphate disodium (Standard)
Adenosine 5'-monophosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-monophosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.
Reference Standards   Adenosine Receptor  
Metabolic or Endocrine Disease  
/
HY-N15719 Dipsacus saponin R
Dipsacus saponin R (Compound 1) is an orally active triterpenoid saponin found in Radix Dipsaci. Dipsacus saponin R promotes bone formation and repair by regulating osteoblast activity or inhibiting osteoclast function. Dipsacus saponin R is promising for research of bone diseases such as osteoporosis and fracture healing.
Others  
/
HY-P991744 Anti-Mouse CXCR4 Antibody (Cx4Mab-1)
Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma.
CXCR  
Chronic Lymphocytic Leukemia   Multiple Myeloma  
/
HY-P991569 PF-04840082
PF-04840082 is a humanized IgG2 monoclonal antibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research.

Species: Human

Wnt  
Metabolic or Endocrine Disease  
/
HY-15893G DMOG (GMP)
DMOG (GMP) is the GMP level of DMOG (HY-15893). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DMOG (GMP) is a HIF-1α stabilizer. DMOG (GMP) promotes the osteogenic, angiogenic, and chondrogenic differentiation of stem cells by stabilizing the expression of HIF-1α. DMOG (GMP) can enhance the osteogenic and angiogenic differentiation potential of stem cells, thereby improving bone regeneration in bone defects. DMOG (GMP) can be used in the research of bone defect repair, vascularized bone regeneration, and the treatment of bone-related diseases (such as osteoporosis and femoral head necrosis) .
Autophagy   HIF/HIF Prolyl-Hydroxylase  
Blood or Cardio-cerebrovascular Disease  
/
HY-P0007 Elcatonin
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect.
Drug Intermediate  
Metabolic or Endocrine Disease  
/
HY-P4839 GLP-2 (1-34) (human)
GLP-2 (1-34) (human) is a polypeptide released from the intestine within minutes after food intake. GLP-2 (1-34) (human) can be used for the research of bone remodeling processes.
Others  
Metabolic or Endocrine Disease  
/
HY-P10133 PRDX3(103-112) SO3 modified, human
PRDX3(103-112) SO3 modified, human is a marker of ferroptosis, and can be used for liver diseases study.
Ferroptosis  
Metabolic or Endocrine Disease  
/
HY-P11358 IRW
IRW is an orally active tripeptide produced from egg white with angiotensin converting enzyme (ACE) inhibitory properties. IRW can prevent high-fat diet (HFD)-induced Non-alcoholic fatty liver disease (NAFLD) by modulating hepatic lipid metabolism and increasing mitochondrial content. IRW decreases hepatic triglyceride content and lipid droplet size. IRW increases the hepatic mitochondrial complexes and citrate synthase activity, phosphorylation of 5’-AMP-activated protein kinase and microsomal triglyceride transfer protein abundance. IRW increases phosphorylated acetyl CoA carboxylase and mitochondrial complexes, IRW can be used for the research of inflammation.
Angiotensin-converting Enzyme (ACE)   Acetyl-CoA Carboxylase   Mitochondrial Metabolism  
Inflammation or Immune System Disease  
/
HY-W018772S6 D-Ribose-d
D-Ribose-d is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gly
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-P11549 pPB peptide
pPB peptide is a cyclic peptide targeting platelet-derived growth factor receptor β (PDGFRβ). Derived from natural platelet-derived growth factor (PDGF), pPB peptide contains arginine and isoleucine as key receptor-binding residues. pPB peptide specifically binds to PDGFRβ, which is highly expressed on the surface of activated hepatic stellate cells (HSC). pPB peptide can be used in studies related to liver fibrosis, liver cirrhosis, and tumor-specific drug delivery.
PDGFR  
Cancer   Lung Fibrosis  
/
HY-P991574 MEDI-5884
MEDI-5884 (REG-101) is a humanized IgG4Pκ neutralizing monoclonal antibody targeting endothelial lipase (EL), with an IC50 of 1.3 nM and 1.7 nM against human and cynomolgus monkey EL, respectively; its Kd values for human and cynomolgus monkey EL are 4.1 nM and 1.6 nM, respectively. MEDI-5884 increases plasma levels of HDL-C, apolipoprotein A1 (ApoA1) and phospholipids, while causing a slight increase in LDL-C and apolipoprotein B (ApoB) levels. MEDI-5884 can be used in research related to cardiovascular diseases, coronary heart disease, coronary atherosclerosis and stable coronary artery disease.

Species: Human

Lipase   Apolipoprotein  
Atherosclerosis and Inflammation   Atherosclerosis  
/
HY-N4145 Procyanidin A3
Procyanidin A3 (Cinnamtannin A3; Cinnamtannin II) is a sub class of Proanthocyanidins (HY-N0794). Proanthocyanidin are a class of polyphenolic that are widely distributed in higher plants, consisted of an electrophilic flavanyl unit. Proanthocyanidin can be used as antioxidant and anti-cancer agent. Proanthocyanidin also exhibit anti-inflammatory, cardioprotective, antibacterial and antifungal properties, which can be used in the treatment of chronic venous insufficiency, capillary fragility, sunburn and retinopathy.
Drug Derivative   Bacterial   Fungal  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-128696R Amlodipine aspartic acid impurity (Standard)
Amlodipine aspartic acid impurity (Amlodipine aspartate) (Standard) is the analytical standard of amlodipine aspartic acid impurity. This product is intended for research and analytical applications. Amlodipine aspartic acid impurity is the impurity of Amlodipine aspartic acid. Amlodipine aspartic acid is a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine aspartic acid impurity can control blood pressure. Amlodipine aspartic acid impurity corrects gut dysbiosis and enhances taurine and hypotaurine metabolism. Amlodipine aspartic acid impurity can be studied in research for NAFLD and hypertension.
Drug Metabolite   Reference Standards   Calcium Channel  
Blood or Cardio-cerebrovascular Disease  
/
HY-P0284B C-telopeptide acetate
C-telopeptide acetate is a cross-linked peptide of type I collagen that is released during bone resorption and correlates with bone mineral density (BMD). C-telopeptide acetate can be used in studies related to postmenopausal osteoporosis.
MMP  
Osteoporosis  
/
HY-P991365 DS-1501
DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Metabolic or Endocrine Disease  
/
HY-P11588 KBP-042
KBP-042 is an orally active amylin receptor activator, a calcitonin receptor activator. KBP-042 induces sustained weight loss, reduces adipose tissue mass, lowers hepatic lipid deposition, increases plasma adiponectin, decreases plasma leptin, and reduces plasma glucose-dependent insulinotropic peptide levels. KBP-042 can be used for the research of obesity and insulin resistance.
Amylin Receptor   CGRP Receptor  
Glucose Metabolism  
/
HY-P4827 pTH (1-84) (dog)
pTH (1-84) dog is a biologically active full-length canine parathyroid hormone, as well as an agonist of PTHR. pTH (1-84) dog can be detected by the "intact" PTH (W-PTH) assay, thus effectively distinguishing inactive C-terminal fragments. In terms of metabolic regulation, it rapidly and persistently stimulates hepatic glucose release, hepatic alanine uptake, and alanine-based gluconeogenesis in conscious fasted dogs, and causes a secondary increase in circulating canine insulin levels due to enhanced glucose release. However, high doses of pTH (1-84) (dog) may induce adverse reactions such as hypercalcemia in dogs. Based on the above characteristics, this hormone can be widely used in studies related to canine hyperadrenocorticism (HAC).
PTHR  
Hypercalcemia  
/
HY-N0732R Jolkinolide B (Standard)
Jolkinolide B (Standard) is the analytical standard of Jolkinolide B (HY-N0732). This product is intended for research and analytical applications. Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
Reference Standards   IAP   Akt   Caspase   NF-κB   TGF-beta/Smad   JAK   Bacterial   Apoptosis  
Cancer   Mycobacterium Tuberculosis Infection   Asthma  
/
HY-163253S HSD17B13-IN-56-d3
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
17β-HSD  
Metabolic or Endocrine Disease  
/
HY-21191S Perfluorobutanesulfonic acid-13C3 sodium
Perfluorobutanesulfonic acid-13C3 sodium (PFBS-13C3 sodium) is the 13C-labeled Perfluorobutanesulfonic acid (HY-21191). Perfluorobutanesulfonic acid (PFBS) is a short-chain perfluoroalkyl substance and the main replacement for perfluorooctanesulfonic acid. Perfluorobutanesulfonic acid induces fat accumulation in human HepG2 hepatoma cells. Perfluorobutanesulfonic acid promotes lipid accumulation by activating PPARγ pathway and triggering oxidative stress, endoplasmic reticulum stress and calcium dyshomeostasis. Perfluorobutanesulfonic acid impairs reproduction and causes developmental disorders in offspring of Caenorhabditis elegans. Perfluorobutanesulfonic acid disrupts pancreatic organogenesis and lipid homeostasis in zebrafish embryos. Perfluorobutanesulfonic acid can be used in environmental toxicology, lipid metabolism and developmental toxicity studies.
Isotope-Labeled Compounds   Biochemical Assay Reagents   PPAR   Reactive Oxygen Species (ROS)  
Lung Cancer   Bacterial Infection   Lipid Metabolism  
/
HY-W127408 Tripalmitolein
1,2,3-Tripalmitoleoyl-rac-glycerol is a triacylglycerol containing palmitoleic acid at the sn-1, sn-2 and sn-3 positions. It reduces erythrocyte deformability in a concentration-dependent manner in the Reid filtration assay. Hepatic levels of 1,2,3-tripalmitoleoyl-rac-glycerol are increased in a JAK2L mouse model of hepatic steatosis. 1,2,3-Tripalmitoleoyl-rac-glycerol plasma levels are reduced in patients with predialysis renal disease.
Biochemical Assay Reagents   Endogenous Metabolite  
/
HY-P3848 Tyr0-Neurokinin A
Tyr0-Neurokinin A is a neuropeptide belongs to tachykinin peptide family. Tyr0-Neurokinin A is an agonist of Tacr2. Tyr0-Neurokinin A can be used in the research of insulin resistance, obesity, diabetes.
Neurokinin Receptor  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P0284 C-telopeptide
C-telopeptide is a cross-linked peptide of type I collagen that is released during bone resorption and correlates with bone mineral density (BMD). C-telopeptide can be used in studies related to postmenopausal osteoporosis.
MMP  
Osteoporosis  
/
HY-123047S Tibolone-d5
Tibolone-d5 is deuterium labeled Tibolone. Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research.
Isotope-Labeled Compounds   Androgen Receptor   Progesterone Receptor   Estrogen Receptor/ERR  
Metabolic or Endocrine Disease  
/
HY-B0515AS Ibandronic Acid-d3 sodium salt
Ibandronic Acid-d3 (sodium) is the deuterium labeled Ibandronic acid. Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis[1][2].
Apoptosis   Isotope-Labeled Compounds  
Cancer  
/
HY-W011012S1 Adenosine 5'-monophosphate-d2 disodium
Adenosine 5'-monophosphate-d2 disodium is the deuterium labeled Adenosine 5'-monophosphate (HY-W011012). Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.
Isotope-Labeled Compounds  
/
HY-117110 Arginylproline
Arginylproline (H-Arg-Pro-OH) is a dipeptide consisted of arginine and proline. Arginylproline reduces intracellular triglyceride (TG) levels stimulated by Oleic acid (HY-N1446), through the peptide transporter 1 (PepT1) pathway.
Proton Pump  
Metabolic or Endocrine Disease  
/
HY-W001288S Indole-4-carboxaldehyde-13C
Indole-4-carboxaldehyde-13C is the 13C-labeled Indole-4-carboxaldehyde (HY-W001288). Indole-4-carboxaldehyde is an ergot alkaloid precursor that regulates glycosylation and inflammation. Indole-4-carboxaldehyde upregulates Glo-1, inhibits MGO-induced NF-κB activation, and suppresses MGO-induced expression of TNF-α and IFN-γ. Indole-4-carboxaldehyde inhibits MGO-induced formation of advanced glycation end products (AGE) and expression of their receptor (RAGE). Indole-4-carboxaldehyde is a core metabolite produced in the pedicels of Summer Black grapes after exogenous gibberellin treatment, and it directly promotes fruit enlargement and fruit set of Summer Black grapes. Indole-4-carboxaldehyde can be used in studies related to hepatic steatosis and plant growth regulation.
Isotope-Labeled Compounds   Glyoxalase (GLO)   NF-κB   TNF Receptor   Drug Intermediate  
Fatty Liver Disease  
/
HY-129159R (-)-Clerosterol (Standard)
(-)-Clerosterol (Standard) is the analytical standard of (-)-Clerosterol. This product is intended for research and analytical applications. (-)-Clerosterol is a natural product that can be isolated from Codium fragile.
Others   Reference Standards  
/
HY-W001189S 1,3-Dithiane-d2
1,3-Dithiane-d2 is the deuterium labeled 1,3-Dithiane (HY-W001189). 1,3-Dithiane is a protected formaldehyde anion equivalent and a sulfur-containing Maillard reaction product. 1,3-Dithiane is found in cooked beef extracts. 1,3-Dithiane is a potent mutagenic agent against S. typhimurium TA98 and TA100. 1,3-Dithiane can be used as a useful marker synthon.
Isotope-Labeled Compounds   Bacterial  
Infection  
/
HY-P991617 AMG-167
AMG-167 is an anti-cancer monoclonal antibody targeting sclerostin. AMG-167 can be studied in research for osteoporosis.

Species: Human

Wnt  
Cancer  
/
HY-120657S 9-PAHSA-d4
9-PAHSA-d4 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
Isotope-Labeled Compounds   CGRP Receptor   NF-κB  
/
HY-W653893 Taurocholic acid-d5 sodium
Taurocholic acid-d5 (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
Isotope-Labeled Compounds   Endogenous Metabolite   VEGFR  
Inflammation or Immune System Disease  
/
HY-107737R 1,2-DLPC (Standard)
1,2-DLPC (Standard) is the analytical standard of 1,2-DLPC (HY-107737). This product is intended for research and analytical applications. 1,2-DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) is a ligand for LRH-1 agonists. 1,2-DLPC is a phospholipid used in the synthesis of liposomes. 1,2-DLPC enhances fat breaKdown and apoptosis in fat cells through a TNFα-dependent pathway, while also inhibiting palmitate-induced insulin resistance through PPARα-mediated inflammation in muscle cells.
Reference Standards   Liposome   Apoptosis   TNF Receptor   PPAR  
/
HY-100713S Temocapril-d5
Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.
Isotope-Labeled Compounds   Angiotensin-converting Enzyme (ACE)  
Blood or Cardio-cerebrovascular Disease  
/
HY-P990252 Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2)
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma.

Species: Mouse

Notch   Interleukin Related   NF-κB   VEGFR   FGFR   NO Synthase  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-120657S1 9-PAHSA-d31
9-PAHSA-d31 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
Isotope-Labeled Compounds   CGRP Receptor   NF-κB  
/
HY-105047 Cholyl-Lys-fluorescein
Cholyl-Lys-fluorescein is a fluorescent-labelled bile salt and a marker of hepatic biliary transporter function. Cholyl-Lys-fluorescein can be used for metabolic research.
Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-N0723R Neomangiferin (Standard)
Neomangiferin (Standard) is the analytical standard of Neomangiferin. This product is intended for research and analytical applications. Neomangiferin is an orally active natural flavonoid. Neomangiferin partially ameliorates non-alcoholic fatty liver disease (NAFLD) by regulating the expression of genes related to free fatty acid uptake and lipid oxidation. Neomangiferin exerts anti-colitis effects by inhibiting Th17/Treg cell differentiation. Neomangiferin exerts anti-aging and lifespan-extending effects by targeting upregulation of bas-1, which in turn activates the autophagy, IIS and MAPK pathways. Neomangiferin has the potential to prevent aseptic loosening of prostheses after total joint arthroplasty due to its significant anti-inflammatory and osteoclastogenesis-inhibiting effects.
Reference Standards   Autophagy   p38 MAPK   TNF Receptor   Interleukin Related   PPAR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N0036R Costunolide (Standard)
Costunolide (Standard) is the analytical standard of Costunolide. This product is intended for research and analytical applications. Costunolide ((+)-Costunolide) is a naturally occurring sesquiterpene lactone, with antioxidative, anti-inflammatory, antiallergic, bone remodeling, neuroprotective, hair growth promoting, anticancer, and antidiabetic properties. Costunolide can induce cell cycle arrest and apoptosis on breast cancer cells.
Reference Standards   Apoptosis   Endogenous Metabolite  
Breast Cancer  
/
HY-P5417 Pancreastatin
Pancreastatin is a biological active peptide. (Pancreastatin (PST) enhances hepatic glucose output leading to diabetes. )
Others  
/
HY-P2588A Osteocalcin (human) TFA
Osteocalcin (Osteocalcin (1-49)) (human) TFA is a vitamin K-dependent bone specific protein. Osteocalcin (human) TFA is chemotactic for several of the cell types frequently found at bone remodeling surfaces.
Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease  
/
HY-P10889 CNI103
CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively blocks the interaction between calcineurin and NFATc3 (KD=16 nM), thereby preventing NFATc3 activation in vitro and in vivo. CNI103 can be used to study acute respiratory distress syndrome (ARDS) and other inflammatory diseases.
Phosphatase  
Inflammation or Immune System Disease  
/
HY-N19066 Cissus quadrangularis extract
Cissus quadrangularis extract contains a variety of bioactive compounds, such as flavonoids, phenolic acids, carotenoids, triterpenoids, vitamins, 3-ketosteroids, minerals, and sterols. Cissus quadrangularis extract can promote fracture healing, reduce bone loss, and increase bone density.
Others  
Metabolic or Endocrine Disease  
/
HY-W018772S14 D-Ribose-d5
D-Ribose-d5 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-N4120 Valechlorine
Valechlorine, an iridoid, is an autophagy enhancer. Valechlorine is effective in alleviating fatty liver by acting as an autophagy enhancer to break down lipid droplets. Valechlorine can be used for the study of nonalcoholic fatty liver disease (NAFLD).
Autophagy  
/
HY-122961 Dehydromiltirone
Dehydromiltirone (1,2-Didehydromiltirone) is a diterpenoid quinone with an anti-inflammatory effect. Dehydromiltirone prevents liver injury by modifying the MAPK and NF-κB signaling pathways, reducing neuroinflammatory responses, and inhibiting platelet aggregation. Dehydromiltirone can be used for osteoporosis research.
NF-κB   p38 MAPK  
Inflammation or Immune System Disease  
/
HY-W355700S 1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine-d31
1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine-d31 is the deuterium labeled 1-Oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (HY-W355700). 1-oleoyl-sn-glycero-3-phosphoethanolamine (LysoPE 18:1) is a lysophosphatidylethanolamine molecule involved in phospholipid metabolism, targeting cell membrane receptors (such as G protein-coupled receptors) to regulate cell signaling pathways. 1-oleoyl-sn-glycero-3-phosphoethanolamine may activate mitogen-activated protein kinase (MAPK) signaling, promote cell migration, regulate inflammatory responses and lipid metabolism, and has both pro-inflammatory and anti-inflammatory activities. 1-oleoyl-sn-glycero-3-phosphoethanolamine is mainly used in the screening of biomarkers for metabolic diseases (such as non-alcoholic fatty liver disease and obesity), as well as the study of the mechanism of lysophospholipids in cell membrane homeostasis and signal transduction.
Isotope-Labeled Compounds  
/
HY-105168 TAK 044
TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage.
Endothelin Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-P3497A Fmoc-Cys-Asp10 TFA
Fmoc-Cys-Asp10 (TFA) is a non-releasable oligopeptide linker, involves in the synthesis of releasable oligopeptide linker. Releasable oligopeptide linker can be used to deliver agent to a bone fracture-homing oligopeptide and reduces fractured femur healing times.
Amino Acid Derivatives  
/
HY-N15723 Dipsacus saponin A
Dipsacus saponin A is an orally active triterpenoid saponin found in the roots of Dipsacus asper. Dipsacus saponin A promotes bone repair by regulating osteoblast activity and inhibiting osteoclast function. Dipsacus saponin A is promising for research of bone diseases such as fracture healing and osteoporosis.
Others  
/
HY-P3497 Fmoc-Cys-Asp10
Fmoc-Cys-Asp10 is a non-releasable oligopeptide linker, involves in the synthesis of releasable oligopeptide linker. Releasable oligopeptide linker can be used to deliver agent to a bone fracture-homing oligopeptide and reduces fractured femur healing times.
Amino Acid Derivatives  
/
HY-W018772S10 D-Ribose-5,5-C-d2
D-Ribose-d2 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-B1151S Climbazole-d4
Climbazole-d4 is the deuterium labeled Climbazole. Climbazole (BAY-e 6975) is a potent antifungal agent. Climbazole also is a potent inducer of rat hepatic cytochrome P450.
Isotope-Labeled Compounds   Fungal  
Infection  
/
HY-P990990 Efsubaglutide alfa
Efsubaglutide alfa is a long-acting humanised GLP-1 receptor agonist. Efsubaglutide alfa binds specifically to the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon release, and promoting β-cell proliferation and increased β-cell mass. Efsubaglutide alfa improves glucose tolerance, increases pancreatic insulin content, and enhances β-cell secretory responses in isolated human islets. Efsubaglutide alfa reduces liver steatosis, lowers NAFLD Activity Scores, improves perisinusoidal collagen features, reduces serum ALT and AST levels, improves fasting glucose and triglyceride levels, and reduces body weight, liver weight and liver-to-body weight ratio. Efsubaglutide alfa can be used for the research of type 2 diabetes. Efsubaglutide alfa can be used for the research of metabolic dysfunction-associated steatohepatitis.

Species: Human

GLP Receptor  
Digestive System Disease   Digestive System Inflammation   Type 2 Diabetes  
/
HY-129159 (-)-Clerosterol
(-)-Clerosterol is a natural product that can be isolated from Codium fragile.
Apoptosis   Bcl-2 Family   Caspase  
/
HY-W770410 9-PAHSA-13C4
9-PAHSA-13C4 is 13C-labeled 9-PAHSA. 9-PAHSAis an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSAsignificantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSAinduces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSAregulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSAdoes not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSAcan be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
Isotope-Labeled Compounds   CGRP Receptor   NF-κB  
/
HY-W011012S Adenosine 5'-monophosphate-13C disodium
Adenosine 5'-monophosphate-13C (disodium) is a 13C-labeled Adenosine 5'-monophosphate (HY-W011012). Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.
Isotope-Labeled Compounds  
/
HY-W592871R 10-Hydroxy-2-decenoic acid (Standard)
10-Hydroxy-2-decenoic acid (Standard) is an analytical standard for 10-Hydroxy-2-decenoic acid (HY-W592871). This product is intended for research and analytical applications.10-Hydroxy-2-decenoic acid (10-HDA) is an orally active unsaturated medium-chain fatty acid with various physiological activities. 10-Hydroxy-2-decenoic acid induces ROS-mediated apoptosis in A549 cells. 10-Hydroxy-2-decenoic acid inhibits VEGF-induced angiogenesis in human venous endothelial cells. 10-Hydroxy-2-decenoic acid alleviates non-alcoholic fatty liver disease (NAFLD) by activating the AMPK-α signaling pathway. 10-Hydroxy-2-decenoic acid protects against bone loss by inhibiting NF-κB signaling downstream of FFAR4. 10-Hydroxy-2-decenoic acid is an antibiotic against many bacteria and fungi, such as Neurospora sitophila, molds and Staphylococcus aureus. 10-Hydroxy-2-decenoic acid has longevity-promoting effects in C. elegans. 10-Hydroxy-2-decenoic acid prevents osteoarthritis by targeting aspartyl β hydroxylase and inhibiting chondrocyte senescence.
Reference Standards   mTOR  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-169332 Piezo1 agonist 1-d2
Piezo1 agonist 1-d2 is a Piezo1 agonist and osteogenesis promoter with an EC50 of 2.21 μM. Piezo1 agonist 1-d2 activates Piezo1 and induces calcium ion influx in mesenchymal stem cells. Piezo1 agonist 1-d2 activates the Erk signaling pathway and promotes osteogenesis of mesenchymal stem cells. Piezo1 agonist 1-d2 alleviates disuse osteoporosis in a hindlimb unloading rat model. Piezo1 agonist 1-d2 can be used for research on osteoporosis.
Piezo Channel   ERK  
Osteoporosis  
/
HY-123115 Leucrose
Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) is an orally active Sucrose (HY-B1779) isomer naturally found in pollen and honey. Leucrose promotes phosphorylation of JAK1 and STAT6, reduces pro-inflammatory mediators and cytokinesas (TNFα, and IL-1β), increases M2 macrophage polarization and suppresses DSS (HY-116282C)-induced colitis. Leucrose suppresses hepatic triglyceride accumulation, improves fasting blood glucose levels, and regulates hepatic lipogenesis and fatty acid β-oxidation in high-fat diet-induced obese mice. Leucrose is slowly hydrolyzed into glucose and fructose by α-glucosidase and acts as as a sugar substitute in diet.
JAK   STAT   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-W018772S1 D-Ribose-13C
D-Ribose-13C is the 13C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-100573S Necrosulfonamide-d4
Necrosulfonamide-d4 is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Isotope-Labeled Compounds   Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Integrin   NO Synthase   Heme Oxygenase (HO)  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P2588 Osteocalcin (human)
Osteocalcin (Osteocalcin (1-49)) (human) is a vitamin K-dependent bone specific protein. Osteocalcin (human) is chemotactic for several of the cell types frequently found at bone remodeling surfaces.
Endogenous Metabolite  
Metabolic or Endocrine Disease   Breast Cancer  
/
HY-P0284A C-telopeptide TFA
C-telopeptide TFA is a cross-linked peptide of type I collagen that is released during bone resorption and correlates with bone mineral density (BMD). C-telopeptide TFA can be used in studies related to postmenopausal osteoporosis.
MMP  
Osteoporosis  
/
HY-N9410S Lysophosphatidylcholine 18:2-d9
Lysophosphatidylcholine 18:2-d9 is deuterium labeled Lysophosphatidylcholine 18:2. Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary
Isotope-Labeled Compounds   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-N0943 (-)-Epiafzelechin
(−)-Epiafzelechin is a COX-1 inhibitor with an IC50 of approximately 15 μM against COX-1 activity. (−)-Epiafzelechin also exhibits DPPH free radical scavenging activity, with an EC50 of 20.9 μM. (−)-Epiafzelechin promotes osteoblast differentiation by increasing ALP activity, ECM collagen content and Runx2 expression, while reducing the growth of osteoclast precursors and RANKL-induced TRAP activity, thereby regulating the bone remodeling process. (−)-Epiafzelechin alleviates ovariectomy-induced bone loss. (−)-Epiafzelechin can be used in studies related to bone remodeling, postmenopausal osteoporosis, inflammatory responses and oxidative stress.
COX   Free Radical Scavengers  
Oxidative Stress and Inflammation   Osteoporosis  
/
HY-W653842 Taurocholic acid-d8 sodium
Taurocholic acid-d8 (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
Isotope-Labeled Compounds   Endogenous Metabolite   VEGFR  
Inflammation or Immune System Disease  
/
HY-128696 Amlodipine aspartic acid impurity
Amlodipine aspartic acid impurity (Amlodipine aspartate) is the impurity of Amlodipine aspartic acid. Amlodipine aspartic acid is a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine aspartic acid impurity can control blood pressure. Amlodipine aspartic acid impurity corrects gut dysbiosis and enhances taurine and hypotaurine metabolism. Amlodipine aspartic acid impurity can be studied in research for NAFLD and hypertension.
Drug Metabolite   Calcium Channel  
Digestive System Disease   Neurodegenerative Disease   Digestive System Inflammation   Hypertension  
/
HY-Y0399S L-Norvaline-d5
L-Norvaline-d5 is the deuterium labeled L-Norvaline. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease.
Isotope-Labeled Compounds   Amyloid-β   TNF Receptor   Arginase  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P991753 Anti-Mouse CCL5 Antibody (R6G9)
Anti-Mouse CCL5 Antibody (R6G9) is a neutralizing agent that binds to CCL5 to inhibit its chemotactic activity towards CD4+ T cells.Anti-Mouse CCL5 Antibody (R6G9) does not suppress CD4+ T cell migration towards infection-derived liver cells, reduce CD4+ T cell hepatic accumulation, or impair CD4+ T cell migratory capacity.Anti-Mouse CCL5 Antibody (R6G9) serves as a tool to assess CCL5’s role in in vivo target cell killing by LCMV-specific CD8+ effector T cells.Anti-Mouse CCL5 Antibody (R6G9) can be used for the research of malaria infection and lymphocytic choriomeningitis virus infection.

Species: Mouse

CXCR  
Plasmodium Infection  
/
HY-W015467 Pyridine-3-sulfonic acid
Pyridine-3-sulfonic acid (Pyridine-3-sulphonic acid) is an orally active structural analog of Nicotine acid (HY-B0143). Pyridine-3-sulfonic acid significantly reduces hepatic cholesterol synthesis in rats but lacks cholesterol-lowering activity. Pyridine-3-sulfonic acid does not interfere with the metabolism of Nicotine acid.
Drug Derivative  
Metabolic or Endocrine Disease  
/
HY-137996 Dehydrovomifoliol
Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .
Akt   mTOR  
Metabolic or Endocrine Disease  
/
HY-N0390S3 L-Glutamine-13C5,15N2,d5
L-Glutamine-13C5,15N2,d5 is the deuterium, 13C-, and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-153476A GIP/GLP-1 dual receptor agonist-1 sodium
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
GLP Receptor   GCGR  
Digestive System Disease   Digestive System Inflammation  
/
HY-B0373S1 Tiopronin-d3
Tiopronin-d3 is the deuterium labeled Tiopronin. Tiopronin is a diffusible antioxidant, an antidote to heavy metal poisoning and a radioprotective agent. Tiopronin can control the rate of cystine precipitation and excretion and has the potential for cystinuria, rheumatoid arthritis and hepatic disorders.
Isotope-Labeled Compounds  
Metabolic or Endocrine Disease  
/
HY-165607S MCB-22-174
MCB-22-174 is a deuterated Piezo1 agonist, with an EC50 value of 6.28 μM. MCB-22-174 remarkably activates the CaMKII/ERK signaling pathway and initiates Ca2+ influx in rMSCs. MCB-22-174 significantly decreases the expression of chondrogenesis markers (Comp, Acan) and adipogenesis markers (Lpl, Fabp4) in MSCs. MCB-22-174 can effectively improve bone quality in hind-limb unloading (HU) model rats. MCB-22-174 can be used for the study of disuse osteoporosis (OP).
Piezo Channel   Isotope-Labeled Compounds   ERK   CaMK  
Metabolic or Endocrine Disease  
/
HY-110251A DFHBI-2T
DFHBI-2T is a membrane-permeable, RNA aptamer-activated fluorescent probe (Ex/Em=500 nm/523 nm), with a Kd value of 1300 nM for the RNA aptamer Spinach2. DFHBI-2T binds to Spinach2, converting the fluorophore to a fluorescent state, stabilizing its planar structure to facilitate the radiative fluorescence decay pathway, and forming a complex with red-shifted excitation and emission peaks. DFHBI-2T can be used for RNA imaging in live cells. It is also applicable to research related to fragile X-associated tremor/ataxia syndrome.
DNA Stain  
Neurological, Eye or Ear Disease  
/
HY-B1684 Mebrofenin
Mebrofenin (SQ 26962) is a type of iminodiacetic acid (IDA). Mebrofenin is available as a ready to use the kit for radio-labeling with Tc-99m. Tc-99m Mebrofenin, a diagnostic agent, is used for hepatobiliary imaging. Tc-99m Mebrofenin is the radiopharmaceutical of choice for the evaluation of hepatic function.
Biochemical Assay Reagents  
/
HY-126109 (±)-8-Prenylnaringenin
(±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen Receptor/ERR) that inhibits ERα and ERβ with IC50s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research.
Estrogen Receptor/ERR   Apoptosis  
Metabolic or Endocrine Disease   Breast Cancer  
/
HY-114118S1 Semaglutide-d8 tetraTFA
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-N0390S4 L-Glutamine-5-13C
L-Glutamine-5-13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-W105704 HEPBS
HEPBS is a zwitterionic buffer with a pH range (7.6-9.0) similar to that of biological systems. HEPBS can be used for cell culture. HEPBS also promotes mRNA delivery.
Biochemical Assay Reagents  
/
HY-P3580A Acetyl Gastric Inhibitory Peptide (human) TFA
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity.
Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-A0020S Eldecalcitol-d6
Eldecalcitol-d6 is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.
VD/VDR  
Metabolic or Endocrine Disease  
/
HY-B0247S Torsemide-d7
Torsemide-d7 is the deuterium labeled Torsemide. Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis.
Isotope-Labeled Compounds  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-113353S Nicotinuric acid-d4
Nicotinuric acid-d4 is the 4-labeled Nicotinuric acid (HY-113353). Nicotinuric acid is an acylglycine and the major catabolite of nicotinic acid (HY-B0143). Its urinary levels correlate with body mass index, blood pressure, blood lipid parameters, and high-sensitivity C-reactive protein. Nicotinuric acid participates in coenzyme-related activities including glycolysis, gluconeogenesis, the citric acid cycle, oxidation, and long-chain fatty acid synthesis in various tissues. Nicotinuric acid is associated with the progression of metabolic syndrome to diabetes and atherosclerotic cardiovascular disease[1]
Isotope-Labeled Compounds   Drug Metabolite  
Glucose Metabolism   Atherosclerosis and Inflammation  
/
HY-D0149 4-(Trifluoromethyl)umbelliferone
4-(Trifluoromethyl)umbelliferone is fluorescent probe substrate for rat hepatic cytochrome P450 enzymes.
Cytochrome P450  
/
HY-P991290 IRAB-B
IRAB-B is a human monoclonal antibody targeting INSR. IRAB-B is an insulin receptor (IR) antagonist and can be used in the study of insulin resistance and diabetes.

Species: Human

Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-W018772S12 D-Ribose-d6
D-Ribose-d6 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-P4060 Pancreatic polypeptide
Pancreatic polypeptide is a peptide secreted by the endocrine PP cells of the pancreas that regulates pancreatic secretory activity and also affects hepatic glycogen stores and gastrointestinal secretion.
Neuropeptide Y Receptor  
Metabolic or Endocrine Disease  
/
HY-W018772S15 D-Ribose(mixture of isomers)-13C5
D-Ribose(mixture of isomers)-13C5 isomers)-13C5 is the 13C labeled D-Ribose(mixture of isomers). D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner.
Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-W012980R Isovaleric acid (Standard)
Isovaleric acid (Standard) is the analytical standard of Isovaleric acid. This product is intended for research and analytical applications. Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders.
Reference Standards   Endogenous Metabolite   AMPK   PKA  
Metabolic or Endocrine Disease  
/
HY-66005S2 Acetaminophen-d7
Acetaminophen-d7 is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent. Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor.
COX   Histone Acetyltransferase   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-W001288 Indole-4-carboxaldehyde
Indole-4-carboxaldehyde is an ergot alkaloid precursor that regulates glycosylation and inflammation. Indole-4-carboxaldehyde upregulates Glo-1, inhibits MGO-induced NF-κB activation, and suppresses MGO-induced expression of TNF-α and IFN-γ. Indole-4-carboxaldehyde inhibits MGO-induced formation of advanced glycation end products (AGE) and expression of their receptor (RAGE). Indole-4-carboxaldehyde is a core metabolite produced in the pedicels of Summer Black grapes after exogenous gibberellin treatment, and it directly promotes fruit enlargement and fruit set of Summer Black grapes. Indole-4-carboxaldehyde can be used in studies related to hepatic steatosis and plant growth regulation.
Glyoxalase (GLO)   NF-κB   TNF Receptor   Drug Intermediate  
Fatty Liver Disease  
/
HY-W110927 Alizarin Red S Indicator (4.3-6.3), IND
Alizarin red S indicator (C.I. 58005) is a reductively active (quinone-based) anthraquinone dye that forms complexes with metal ions (such as zirconium, calcium) or boric acid to label calcium deposition and perform electrochemical sensing functions. Alizarin Red S undergoes reversible redox reactions (for electrochemical detection) and irreversible chelation (for bone staining). Alizarin Red S is mainly used in bone metabolism research (labeling mineralized tissue), sugar detection (boric acid-sugar competition system) and metal ion sensing (such as zirconium ion detection)， and can be used in osteoporosis and metabolic disease research.
Biochemical Assay Reagents   Fluorescent Dye  
/
HY-W251393 S-(2-Carboxypropyl)-L-cysteine
S-(2-Carboxypropyl)-L-cysteine (β-Isobuteine) is a urine metabolite, a metabolic marker of leigh-like syndrome.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-113353 Nicotinuric acid
Nicotinuric acid is an acylglycine and the major catabolite of nicotinic acid (HY-B0143). Its urinary levels correlate with body mass index, blood pressure, blood lipid parameters, and high-sensitivity C-reactive protein. Nicotinuric acid participates in coenzyme-related activities including glycolysis, gluconeogenesis, the citric acid cycle, oxidation, and long-chain fatty acid synthesis in various tissues. Nicotinuric acid is associated with the progression of metabolic syndrome to diabetes and atherosclerotic cardiovascular disease[1]
Drug Metabolite  
Glucose Metabolism   Atherosclerosis and Inflammation  
/
HY-N2413 Gomisin D
Gomisin D is an orally active lignan that binds to PDGFRβ with a Kd of 10 μM. By targeting PDGFRβ to regulate signaling pathways, Gomisin D inhibits the activation and proliferation of hepatic stellate cells and promotes their apoptosis, thereby ameliorating hepatic fibrosis. Gomisin D exhibits multiple activities such as photoprotection, antimelanogenesis, antioxidant effects, and hypoglycemic activity. Gomisin D can be used in studies related to diabetes, Alzheimer's disease, and hepatic fibrosis.
PDGFR   UGT   Reactive Oxygen Species (ROS)   Apoptosis   Tyrosinase   p38 MAPK   Akt   ERK   COX   Interleukin Related  
Inflammation or Immune System Disease   Glucose Metabolism   Alzheimer's Disease   Hepatic Fibrosis  
/
HY-114118S Semaglutide-d8
Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK   GLP Receptor   Apoptosis   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-N1941 Isosinensetin
Isosinensetin is a flavonoid compound and an inhibitor of HIV-1 protease and PTP1B (IC50: 2.61 µM; Ki: 0.92 µM). Isosinensetin inhibits P-glycoprotein (P-gp) in MDR1-MDCKII cells. Isosinensetin has multiple activities such as anti-tumor, anti-viral, anti-inflammatory, and antioxidant effects. Isosinensetin can be used in the research of various diseases including cancer, inflammation, osteoporosis, diabetes, etc.
P-glycoprotein   Bacterial   HIV Protease   Phosphatase   Reactive Oxygen Species (ROS)   NF-κB   p38 MAPK   ERK   JNK   Calcium Channel  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Glucose Metabolism   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
/
HY-N6857 Armepavine
Armepavine, found in Nelumbo nucifera, is an orally active NF-κB inhibitor. Armepavine attenuates expression of p-p65, α-SMA, p-JNK1/2, p-ERK1/2, p-p38α stimulated by TNF-α and LPS. Armepavine suppresses NF-κB nuclear translocation, IκBα phosphorylation, and collagen deposition. Armepavine can be used for the research of hepatic fibrosis and leukemia.
AP-1   NF-κB   p38 MAPK   ERK   JNK  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity  
/
HY-15001G Stemregenin 1 (GMP)
Stemregenin 1 (SR1) (GMP) is a GMP-grade Stemregenin 1 (HY-15001). GMP-grade small molecules can be used as adjuvants in cell therapy. Stemregenin 1 is a potent aryl hydrocarbon receptor (AhR) antagonist with an IC50 of 127 nM. Stemregenin 1 (GMP) can competitively bind to AhR and inhibit its nuclear translocation, inhibiting osteoclastogenesis and promoting hematopoietic progenitor cell expansion by blocking the AhR-c-src-NF-κB/p-ERK MAPK-NFATc1 signaling pathway. Stemregenin 1 (GMP) can be used for the study of osteoporosis, in vitro expansion of hematopoietic stem cells, and the study of the mechanism of bone metabolic diseases.
Aryl Hydrocarbon Receptor  
Cancer  
/
HY-W009417 Cedryl acetate
Cedryl acetate is an orally active α-glucosidase inhibitor with an IC50 of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome.
Environmental Pollutants   Glycosidase  
Obesity  
/
HY-126359 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (SLPC; 18:0-18:2 PC) is an endogenous phospholipid marker molecule in the glycerophospholipid metabolic pathway. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine is a core component of the phospholipid bilayer of biological membranes and a key responsive lipid for radiation injury and cardiometabolic diseases. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine constitutes the phospholipid bilayers of cell membranes and high-density lipoprotein (HDL), and regulates the core activity of lipoprotein functional homeostasis. The content of 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine in mouse serum shows a significant dose-dependent decrease with increasing ionizing radiation dose, and its level in human HDL also decreases significantly in metabolic syndrome. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can serve as a biological dosimeter marker for ionizing radiation injury, and is used for rapid and accurate assessment of radiation absorbed dose in exposed individuals. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can also act as a lipidomics research target for cardiometabolic diseases such as lipid metabolic syndrome and early-onset coronary heart disease.
Endogenous Metabolite  
Metabolic or Endocrine Disease   Heart Disease  
/
HY-N9914R D-Psicose (Standard)
D-Psicose (Standard) is the analytical standard of D-Psicose (HY-N9914). This product is intended for research and analytical applications. D-psicose is an orally active rare sugar. D-psicose inhibits p38-MAPK phosphorylation and MCP-1 expression. D-psicose inhibits the AGEs/RAGE/NF-κB pathway. D-psicose protects pancreatic β-islets, improves hyperglycemia and high-fat diet-induced non-alcoholic fatty liver disease.
Reference Standards   p38 MAPK   NF-κB  
Metabolic or Endocrine Disease  
/
HY-N6588 3,4,5-Tricaffeoylquinic acid
3,4,5-Tricaffeoylquinic acid (3,4,5-triCQA) inhibits tumor necrosis factor-α-stimulated production of inflammatory mediators in keratinocytes via suppression of Akt- and NF-κB-pathways. 3,4,5-Tricaffeoylquinic acid induces cell cycle arrest at G0/G1, actin cytoskeleton organization, chromatin remodeling, neuronal differentiation, and bone morphogenetic protein signaling in human neural stem cells. 3,4,5-Tricaffeoylquinic acid has the potential for the research of aging-associated diseases.
Akt   NF-κB  
Inflammation or Immune System Disease  
/
HY-B0171S Antipyrine-d3
Antipyrine-d3 is the deuterium labeled Antipyrine. Antipyrine (Phenazone) is an antipyretic and analgesic. Antipyrine can be used as a probe agent for oxidative agent metabolism. Antipyrine has been widely used in assessment of hepatic oxidative capacity.
Isotope-Labeled Compounds  
Inflammation or Immune System Disease  
/
HY-W423191 Maltobionic acid
Maltobionic acid (4-O-α-D-Glucopyranosyl-D-gluconic acid) is an orally active oligosaccharide and iron chelator with antibacterial activity. Maltobionic acid inhibits the expression of NFATc1, suppresses osteoclast differentiation, inhibits bone resorption, and increases serum calcitonin levels. Maltobionic acid protects mammalian cells from hydrogen peroxide (H2O2)-induced oxidative damage; resists fermentation by the gut microbiota; and exhibits anti-digestive and anti-fermentative properties. Maltobionic acid can be used in research related to osteoporosis, bacterial infections, and constipation.
Nuclear Factor of activated T Cells (NFAT)   Bacterial  
Bacterial Infection   Osteoporosis  
/
HY-P4823 pTH (1-37) (human)
PTH (1-37) human is an adenylate cyclase stimulator and a normocalcemic regulator. PTH (1-37) human participates in cAMP-dependent signal transduction to affect the proliferation of skeletal tissue cells and bone metabolism. PTH (1-37) human induces cyclic adenosine monophosphate responses in human primary osteoblast-like cells and is also widely used in osteoporosis-related research.
Adenylate Cyclase   PTHR  
Osteoporosis  
/
HY-W145486 Calcium gluconate
Calcium gluconate is an orally effective calcium salt supplement. Calcium gluconate reduces elevated serum potassium, decreased serum calcium, and postoperative myalgia associated with succinylcholine administration. Calcium gluconate restores calcium homeostasis, skeletal integrity, bone mineralization and bone density, and maintains levels of parathyroid hormone, bone resorption markers and osteoclasts. Calcium gluconate reverses LPS (HY-D1056)-induced ERK phosphorylation, inflammatory cytokine release and acute lung injury, alleviates airway inflammatory damage and suppresses immune responses. Calcium gluconate can be used in research related to postoperative myalgia, osteoporosis/osteomalacia and acute lung injury.
Environmental Pollutants   Biochemical Assay Reagents  
Postoperative Pain   Acute Lung Injury   Osteoporosis  
/
HY-W250120 Konjac glucomannan (Viscosity≥15000mPa.s)
Konjac glucomannan (Viscosity≥15000mPa.s) is an orally active acetylated (1-4)-β-D-glucomannan with multiple biological activities including anti-diabetic, anti-obesity, anti-inflammatory effects, as well as film-forming and gelling properties. Konjac glucomannan (Viscosity≥15000mPa.s) forms a defensive coating on the intestinal surface, reducing levels of blood glucose, cholesterol, triglycerides and blood pressure; it is specifically degraded by colonic β-mannanase produced by human colonic bacteria. Konjac glucomannan (Viscosity≥15000mPa.s) can be used as a food additive, dietary supplement and excipient for oral colon-targeted drug delivery systems. Konjac glucomannan (Viscosity≥15000mPa.s) is applicable to research related to various diseases such as type 2 diabetes, obesity, atopic dermatitis and metabolic syndrome, as well as research in fields including biotechnology, pharmaceuticals and tissue engineering.
Biochemical Assay Reagents   Drug Intermediate  
Atopic Dermatitis   Type 2 Diabetes   Obesity  
/
HY-107830 Methyl cholate
Methyl cholate is a bile acid analog and a specific inhibitor of TcdB toxin from Clostridioides difficile. Methyl cholate exerts a stronger selective inhibitory effect on TcdB than on TcdA. Methyl cholate induces conformational stabilization by binding to a unique site of TcdB, thereby blocking the binding of the toxin to host receptors and its self-processing process. Methyl cholate effectively protects human fibroblasts from TcdB-induced cytopathic effects. Methyl cholate exhibits dose-dependent anti-hepatic fibrosis activity in both cellular and zebrafish models, and significantly reduces the expression levels of α-SMA and COL-I. Methyl cholate is suitable for in-depth research in the fields of Clostridioides difficile infection and hepatic fibrosis.

Source: Aspergillus niger

Endogenous Metabolite   Collagen  
Bacterial Infection   Hepatic Fibrosis  
/
HY-124081 N-Oleoyl-L-serine
N-Oleoyl-L-Serine is an endogenous amide of long-chain fatty acids with ethanolamine (N-acyl amides). N-Oleoyl-L-Serine is a lipid regulator of bone remodeling and stimulates osteoclast apoptosis. N-Oleoyl-L-Serine can be used for antiosteoporotic drug discovery development.
Apoptosis  
Metabolic or Endocrine Disease  
/
HY-114118CP Semaglutide (crude)
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P99614 Fazpilodemab
Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD).

Species: Human

FGFR  
Metabolic or Endocrine Disease  
/
HY-141578 C18:1-Ceramide
C18:1-Ceramide is a ceramide subspecies belonging to bioactive lipids. C18:1-Ceramide exhibits activities of inducing skeletal muscle insulin resistance and affecting metabolism. C18:1-Ceramide can be used in the research of obesity, type 2 diabetes (T2D), insulin resistance and other related metabolic diseases.
Endogenous Metabolite  
Type 2 Diabetes   Insulin Resistance   Obesity  
/
HY-P5390A GIP, rat TFA
GIP, rat TFA is a bioactive peptide derived from rats. GIP, rat TFA inhibits GIP-mediated postprandial insulin release as well as GIP-promoted glucose uptake in the upper small intestine. GIP, rat TFA can be used in research related to insulin resistance, glucose intolerance, and type 2 diabetes.
Insulin Receptor   Glycosidase  
Type 2 Diabetes   Insulin Resistance  
/
HY-127143 Sterculic acid
Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC50 value of 0.9 μM.
Stearoyl-CoA Desaturase (SCD)  
Inflammation or Immune System Disease  
/
HY-W018004 L-Homocitrulline
L-Homocitrulline is a carbamoylated derivative amino acid and a structural analog of L-citrulline. L-Homocitrulline serves not only as an intermediate in polypeptide synthesis but also converts into a variety of cyclic derivatives under enzymatic or acidic conditions. The level of L-Homocitrulline is significantly elevated in the serum of patients with non-alcoholic fatty liver disease (NAFLD), with high diagnostic accuracy. L-Homocitrulline also exists in patients with related diseases such as hypercitrullinemia. L-Homocitrulline is a key biomarker for monitoring abnormal liver metabolism and is widely used in NAFLD research.
Amino Acid Derivatives   Endogenous Metabolite  
Digestive System Disease   Digestive System Inflammation  
/
HY-N0390S6 L-Glutamine-13C5,15N2
L-Glutamine-13C5,15N2 is the 13C- and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
Isotope-Labeled Compounds   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-114118S3 Semaglutide-13C6,15N TFA
Semaglutide-13C6,15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK   GLP Receptor   Apoptosis   Bcl-2 Family  
Metabolic or Endocrine Disease  
/
HY-P3075 pTH-Related Protein (1-34) (human,mouse,rat)
pTH-Related Protein (1-34) (human, mouse, rat), a fragment of parathyroid hormone-related protein, is an anabolic agent. pTH-Related Protein (1-34) (human, mouse, rat) can be used for postmenopausal osteoporosis study.
Thyroid Hormone Receptor  
Inflammation or Immune System Disease  
/
HY-125848 Ginsenoside F2
Ginsenoside F2 is an orally active bioactive compound that participates in the regulation of metabolism and inflammation. Ginsenoside F2 promotes the phosphorylation of AMPK and ACC, binds to PPARγ, inhibits the phosphorylation of MAPK, activates the PI3K/AKT/GSK-3β pathway, reduces GLRX expression, and regulates lipid metabolism. Ginsenoside F2 reduces ROS production and MDA levels, restores SOD activity in cells, and alleviates oxidative stress. Ginsenoside F2 induces cell apoptosis (Apoptosis) and increases the number of cleaved caspase-3-positive cells. Ginsenoside F2 reduces body weight gain, adipose tissue weight and serum lipid levels in obese mice, and activates the hepatic AMPK signaling pathway and the expression of antioxidant enzymes. Ginsenoside F2 alleviates atopic dermatitis in mice by inhibiting inflammation and reshaping the gut microbiota. Ginsenoside F2 is applicable to research related to insulin resistance, obesity, atopic dermatitis, liver cancer, glioblastoma and glioma.
Apoptosis   AMPK   PPAR   p38 MAPK   PI3K   Akt   GSK-3   Reactive Oxygen Species (ROS)   SOD   Caspase  
Liver Cancer   Glioblastoma   Atopic Dermatitis   Obesity  
/
HY-N3021 D-chiro-Inositol
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome.
Endogenous Metabolite   NF-κB   TNF Receptor   FOXO   Microtubule/Tubulin  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Glucose Metabolism   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
/
HY-P991219 Anti-IL11RA Antibody (X209)
Anti-IL11RA Antibody (X209) (EnX209) is a human-derived IgG4, κ-type antibody inhibitor targeting IL11RA, with a KD of 6 nM. Anti-IL11RA Antibody (X209) blocks the IL11RA signaling pathway, inhibits ERK-dependent activation, and reduces the activation level of ERK1/2. Anti-IL11RA Antibody (X209) exerts a protective effect against fibrosis. Anti-IL11RA Antibody (X209) is applicable to studies related to liver fibrosis, cardiac fibrosis and other related conditions. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003).

Species: Human

Interleukin Related   ERK   MMP  
Inflammation or Immune System Disease  
/
HY-129109 NBD-Pen
NBD-Pen is the first fluorescence probe for lipid radicals with high selectivity and sensitivity (λex: 470 nm, λem: 530 nm). NBD-Pen specifically detects lipid derived radicals over other reactive species present in biological systems, including H2O2, ClO-, O2-?, and ?OH. NBD-Pen directly detects lipid radicals in living cells by turn-on fluorescence. NBD-Pen decreases inflammation, apoptosis, and oxidative stress markers. NBD-Pen can be studied in various disease models such as hepatic carcinoma.
Fluorescent Dye  
Cancer   Inflammation or Immune System Disease  
/
HY-Y0399 L-Norvaline
L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease.
Amyloid-β   TNF Receptor   Arginase  
Metabolic or Endocrine Disease   Breast Cancer   Alzheimer's Disease   Lung Fibrosis  
/
HY-P990165 Anti-Mouse RANKL/CD254 Antibody (IK22/5)
Anti-Mouse RANKL/CD254 Antibody (IK22/5) is an anti-mouse RANKL/CD254 IgG2a monoclonal antibody. Anti-Mouse RANKL/CD254 Antibody (IK22/5) inhibits osteoclast formation and activity by specifically blocking the binding of RANKL and RANK. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can inhibit the expression of MuRF1/Trogin-1 and activation of NF-κB. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can be used for research on cancer such as melanoma or colon cancer and osteoporosis.

Species: Mouse

RANKL/RANK   E1/E2/E3 Enzyme   NF-κB  
Colorectal Cancer   Osteoporosis  
/
HY-P99186 Blosozumab
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis.

Species: Human

Others  
/
HY-126995 Glycohyodeoxycholic acid
Glycohyodeoxycholic acid is a glycine-conjugated bile acid and also a metabolite of Hyodeoxycholic acid (HY-N0169). The serum level of Glycohyodeoxycholic acid is negatively correlated with the severity of non-alcoholic fatty liver disease. Glycohyodeoxycholic acid can be used in research related to non-alcoholic fatty liver disease.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-N0390R L-Glutamine (Standard)
L-Glutamine (Standard) is the analytical standard of L-Glutamine (HY-N0390). This product is intended for research and analytical applications. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.

Source: Human Blood, Breast Milk, Cerebrospinal Fluid (CSF), Feces, Saliva, Sweat, Urine

Reference Standards   mGluR   Ferroptosis   Environmental Pollutants   Endogenous Metabolite   HIF/HIF Prolyl-Hydroxylase   mTOR   STAT   NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P11274A Zenagamtide sodium
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
Amylin Receptor   Insulin Receptor   GCGR  
Metabolic or Endocrine Disease  
/
HY-P4153 Enlicitide chloride
Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders.
PCSK9  
Blood or Cardio-cerebrovascular Disease  
/
HY-N9410 Lysophosphatidylcholine 18:2
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P2273 Calcitonin (human)
Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research.
CGRP Receptor  
Metabolic or Endocrine Disease  
/
HY-P77989 LRP-5 Protein, Human (HEK293, mFc)
The LRP-5 protein functions as a coreceptor, cooperating with Frizzled receptors to initiate the canonical Wnt signaling pathway. It is critical for cell fate determination and self-renewal and plays an important role in posterior ectoderm patterning during gastrulation and bone development by affecting osteoblast proliferation and differentiation. LRP-5 Protein, Human (HEK293, mFc) is the recombinant human-derived LRP-5 protein, expressed by HEK293 , with C-mFc labeled tag.

Species: Human; Source: HEK293

/
HY-P7603 Arginase-2/ARG2 Protein, Human (His)
Arginase-2/ARG2 Protein, Human (His) expresses in E. coli with a His tag at the N-terminus. Arginase-2 (Arg2) acts as a fasting-induced hepatocyte factor that protects against hepatic and peripheral fat accumulation, hepatic inflammatory responses, and insulin and glucose intolerance in obese murine models.

Species: Human; Source: E. coli

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P70838 HEPACAM Protein, Human (HEK293, His)
HEPACAM proteins are key regulators of cell motility, interacting with the extracellular matrix to inhibit cell growth and maintain cellular homeostasis. HEPACAM forms homodimers through cis interactions, is a component of the MLC1, TRPV4, AQP4 and ATP1B1 complexes and participates in key molecular interactions. HEPACAM Protein, Human (HEK293, His) is the recombinant human-derived HEPACAM protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Cell Adhesion Molecules (CAMs)

/
HY-P71203 PHS Protein, Human (His)
PHS protein is crucial in tetrahydrobiopterin biosynthesis and has the dual function of hindering the formation of 7-pterin and promoting quinone-BH2. It also acts as a coactivator of HNF1A-dependent transcription, affecting HNF1A dimerization and enhancing its activity. PHS Protein, Human (His) is the recombinant human-derived PHS protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Lyases (EC 4)

/
HY-P72090 Arginase-2/ARG2 Protein, Mouse (His-SUMO)
Arginase-2 (ARG2) is a multifunctional regulator central to the regulation of arginine metabolism and nitric oxide synthesis outside the urea cycle. In addition to its hepatic effects, ARG2 affects innate and adaptive immune responses, negatively affecting the survival of activated CD4(+) and CD8(+) T cells. Arginase-2/ARG2 Protein, Mouse (His-SUMO) is the recombinant mouse-derived Arginase-2/ARG2 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

Species: Mouse; Source: E. coli

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P700562 ANGPTL4/Angiopoietin-related 4 Protein, Human (GST)
ANGPTL4 protein mediates lipoprotein lipase (LPL) inactivation, regulating triglyceride clearance and lipid metabolism. It also affects glucose homeostasis, insulin sensitivity, endothelial cell function, and angiogenesis. Cleaved ANGPTL4 is more active in LPL inactivation, highlighting its multifaceted role in metabolic and vascular regulation. ANGPTL4/Angiopoietin-related 4 Protein, Human (GST) is the recombinant human-derived ANGPTL4/Angiopoietin-related 4 protein, expressed by E. coli , with N-GST labeled tag.

Species: Human; Source: E. coli

Cytokines and Growth Factors Angiopoietins Angiopoietin Like 4

/
HY-P703222 HNF1A Protein, Human (His, Strep)
HNF1A Protein, Human (His, Strep) is the recombinant human-derived HNF1A, expressed by E. coli , with Strep, His labeled tag. ,

Species: Human; Source: E. coli

/
HY-P703720 ASGR1 Protein, Cynomolgus (HEK293, His)

Species: Cynomolgus; Source: HEK293

/
HY-P705455 Arginase-2/ARG2 Protein, Human (332a.a, His)

Species: Human; Source: E. coli

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P810849 Arginase 2 Antibody
Arginase 2 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Arginase 2.

Host: Rabbit; Reactivity: Human, Monkey

Polyclonal Antibodies Primary Antibodies

/
HY-P811804 AVPR1A Antibody (YA10275)
AVPR1A Antibody (YA10275) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to AVPR1A.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P811804A AVPR1A Antibody (YA10275) (PBS only)
AVPR1A Antibody (YA10275) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to AVPR1A.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P811951 SKIC3 Antibody(YA10422)
SKIC3 Antibody(YA10422) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SKIC3.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P811951A SKIC3 Antibody(YA10422) (PBS only)
SKIC3 Antibody(YA10422) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SKIC3.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P83245 HLF Antibody (YA2990)
HLF Antibody (YA2990) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLF.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83245A HLF Antibody (YA2990)(PBS only)
HLF Antibody (YA2990) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLF.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P810897 Hepatic Lipase Antibody
Hepatic Lipase Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Hepatic Lipase.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P811281 Vasopressin V1a Receptor Antibody
Vasopressin V1a Receptor Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Vasopressin V1a Receptor.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P87163 ketohexokinase Antibody (YA6856)
ketohexokinase Antibody (YA6856) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ketohexokinase.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-K6304 Human iPSC/ESC Hepatocyte Induction Differentiation Kit

MCE Human iPSC/ESC Hepatocyte Induction Differentiation Kit enables the efficient generation of hepatocyte-like cells with a high degree of maturation within 21 d. The resulting cells stably express multiple key hepatic functional markers, including albumin (ALB), cytochrome P450 (CYP) family enzymes, and other liver-specific functional molecules, and exhibit typical hepatocellular phenotypes and functions.

Cell Biology 3D Cell Culture PSC Induction Product Series

/

References

[1]. Musso G, et al. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med. 2013;19 (9):522-535.  

[2]. Pacifico L, et al. Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease. World J Gastroenterol. 2013;19 (25):4007-4014.  

[3]. Su YH, et al. Nonalcoholic fatty liver disease is associated with decreased bone mineral density in adults: a systematic review and meta-analysis. J Bone Miner Res. 2023;38 (8):1092-1103.  

[4]. Khanmohammadi S, et al. Effects of metabolic dysfunction-associated steatotic liver disease on bone density and fragility fractures: associations and mechanisms. J Obes Metab Syndr. 2024;33 (2):108-120.  

[5]. Liu Z, et al. Reduced serum IGF-1 associated with hepatic osteodystrophy is a main determinant of low cortical but not trabecular bone mass. J Bone Miner Res. 2018;33 (1):123-136.  

[6]. Pan B, et al. Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Osteoporos Int. 2022;33 (11):2275-2286.  

[7]. Kim G, et al. Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease. PLoS One. 2017;12 (7):e0182202.  

[8]. Pei X, et al. Mendelian-randomization study revealed causal relationship between nonalcoholic fatty liver disease and osteoporosis/fractures. J Gastroenterol Hepatol. 2024;39 (5):847-857.  

[9]. Chondrogianni ME, et al. Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe. Front Endocrinol (Lausanne). 2024;15:1344376.  

Keywords

metabolic dysfunction-associated steatotic liver disease | MASLD | nonalcoholic fatty liver disease | NAFLD | bone mineral density | osteoporosis | fragility fracture | metabolic syndrome | insulin resistance | liver-bone axis | bone remodeling | hepatic osteodystrophy